<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for paracetamol (acetaminophen) overdose - Chiew, AL - 2018 | Cochrane Library</title> <meta content="Interventions for paracetamol (acetaminophen) overdose - Chiew, AL - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003328.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for paracetamol (acetaminophen) overdose - Chiew, AL - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003328.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003328.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for paracetamol (acetaminophen) overdose" name="citation_title"/> <meta content="Angela L Chiew" name="citation_author"/> <meta content="Christian Gluud" name="citation_author"/> <meta content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Jesper Brok" name="citation_author"/> <meta content="Rigshospitalet" name="citation_author_institution"/> <meta content="Nick A Buckley" name="citation_author"/> <meta content="University of Sydney" name="citation_author_institution"/> <meta content="nicholas.buckley@sydney.edu.au" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD003328.pub3" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/02/23" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003328.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003328.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003328.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acetaminophen [pharmacokinetics, *poisoning]; Acetylcysteine [therapeutic use]; Analgesics, Non-Narcotic [pharmacokinetics, *poisoning]; Antidotes [therapeutic use]; Charcoal [therapeutic use]; Cysteamine [therapeutic use]; Dimercaprol [therapeutic use]; Drug Overdose [mortality, therapy]; Gastric Lavage; Intestinal Absorption; Liver Failure, Acute [chemically induced, epidemiology, surgery]; Liver Transplantation; Methionine [therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003328.pub3&amp;doi=10.1002/14651858.CD003328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="mV7VuqgF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003328\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003328\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003328\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003328\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","pt","ms","pl","th","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003328.pub3",title:"Interventions for paracetamol (acetaminophen) overdose",firstPublishedDate:"Feb 23, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hepato‐Biliary Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003328.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003328.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003328.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003328.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003328.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003328.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003328.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003328.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003328.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003328.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>19636 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003328.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-sec-0121"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-sec-0075"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-sec-0108"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/appendices#CD003328-sec-0126"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/table_n/CD003328StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/table_n/CD003328StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for paracetamol (acetaminophen) overdose</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/information#CD003328-cr-0002">Angela L Chiew</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/information#CD003328-cr-0003">Christian Gluud</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/information#CD003328-cr-0004">Jesper Brok</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003328.pub3/information#CD003328-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Nick A Buckley</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/information/en#CD003328-sec-0130">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 23 February 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003328.pub3">https://doi.org/10.1002/14651858.CD003328.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003328-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003328-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003328-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003328-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/th#CD003328-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003328-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003328-abs-0001" lang="en"> <section id="CD003328-sec-0001"> <h3 class="title" id="CD003328-sec-0001">Background</h3> <p>Paracetamol (acetaminophen) is the most widely used non‐prescription analgesic in the world. Paracetamol is commonly taken in overdose either deliberately or unintentionally. In high‐income countries, paracetamol toxicity is a common cause of acute liver injury. There are various interventions to treat paracetamol poisoning, depending on the clinical status of the person. These interventions include inhibiting the absorption of paracetamol from the gastrointestinal tract (decontamination), removal of paracetamol from the vascular system, and antidotes to prevent the formation of, or to detoxify, metabolites. </p> </section> <section id="CD003328-sec-0002"> <h3 class="title" id="CD003328-sec-0002">Objectives</h3> <p>To assess the benefits and harms of interventions for paracetamol overdosage irrespective of the cause of the overdose. </p> </section> <section id="CD003328-sec-0003"> <h3 class="title" id="CD003328-sec-0003">Search methods</h3> <p>We searched The Cochrane Hepato‐Biliary Group Controlled Trials Register (January 2017), CENTRAL (2016, Issue 11), MEDLINE (1946 to January 2017), Embase (1974 to January 2017), and Science Citation Index Expanded (1900 to January 2017). We also searched the World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov database (US National Institute of Health) for any ongoing or completed trials (January 2017). We examined the reference lists of relevant papers identified by the search and other published reviews. </p> </section> <section id="CD003328-sec-0004"> <h3 class="title" id="CD003328-sec-0004">Selection criteria</h3> <p>Randomised clinical trials assessing benefits and harms of interventions in people who have ingested a paracetamol overdose. The interventions could have been gastric lavage, ipecacuanha, or activated charcoal, or various extracorporeal treatments, or antidotes. The interventions could have been compared with placebo, no intervention, or to each other in differing regimens. </p> </section> <section id="CD003328-sec-0005"> <h3 class="title" id="CD003328-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data from the included trials. We used fixed‐effect and random‐effects Peto odds ratios (OR) with 95% confidence intervals (CI) for analysis of the review outcomes. We used the Cochrane 'Risk of bias' tool to assess the risks of bias (i.e. systematic errors leading to overestimation of benefits and underestimation of harms). We used Trial Sequential Analysis to control risks of random errors (i.e. play of chance) and GRADE to assess the quality of the evidence and constructed 'Summary of findings' tables using GRADE software. </p> </section> <section id="CD003328-sec-0006"> <h3 class="title" id="CD003328-sec-0006">Main results</h3> <p>We identified 11 randomised clinical trials (of which one acetylcysteine trial was abandoned due to low numbers recruited), assessing several different interventions in 700 participants. The variety of interventions studied included decontamination, extracorporeal measures, and antidotes to detoxify paracetamol's toxic metabolite; which included methionine, cysteamine, dimercaprol, or acetylcysteine. There were no randomised clinical trials of agents that inhibit cytochrome P‐450 to decrease the activation of the toxic metabolite <i>N</i> ‐acetyl‐<i>p</i>‐benzoquinone imine. </p> <p>Of the 11 trials, only two had two common outcomes, and hence, we could only meta‐analyse two comparisons. Each of the remaining comparisons included outcome data from one trial only and hence their results are presented as described in the trials. All trial analyses lack power to access efficacy. Furthermore, all the trials were at high risk of bias. Accordingly, the quality of evidence was low or very low for all comparisons. Interventions that prevent absorption, such as gastric lavage, ipecacuanha, or activated charcoal were compared with placebo or no intervention and with each other in one four‐armed randomised clinical trial involving 60 participants with an uncertain randomisation procedure and hence very low quality. The trial presented results on lowering plasma paracetamol levels. Activated charcoal seemed to reduce the absorption of paracetamol, but the clinical benefits were unclear. Activated charcoal seemed to have the best risk:benefit ratio among gastric lavage, ipecacuanha, or supportive treatment if given within four hours of ingestion. There seemed to be no difference between gastric lavage and ipecacuanha, but gastric lavage and ipecacuanha seemed more effective than no treatment (very low quality of evidence). Extracorporeal interventions included charcoal haemoperfusion compared with conventional treatment (supportive care including gastric lavage, intravenous fluids, and fresh frozen plasma) in one trial with 16 participants. The mean cumulative amount of paracetamol removed was 1.4 g. One participant from the haemoperfusion group who had ingested 135 g of paracetamol, died. There were no deaths in the conventional treatment group. Accordingly, we found no benefit of charcoal haemoperfusion (very low quality of evidence). Acetylcysteine appeared superior to placebo and had fewer adverse effects when compared with dimercaprol or cysteamine. Acetylcysteine superiority to methionine was unproven. One small trial (low quality evidence) found that acetylcysteine may reduce mortality in people with fulminant hepatic failure (Peto OR 0.29, 95% CI 0.09 to 0.94). The most recent randomised clinical trials studied different acetylcysteine regimens, with the primary outcome being adverse events. It was unclear which acetylcysteine treatment protocol offered the best efficacy, as most trials were underpowered to look at this outcome. One trial showed that a modified 12‐hour acetylcysteine regimen with a two‐hour acetylcysteine 100 mg/kg bodyweight loading dose was associated with significantly fewer adverse reactions compared with the traditional three‐bag 20.25‐hour regimen (low quality of evidence). All Trial Sequential Analyses showed lack of sufficient power. Children were not included in the majority of trials. Hence, the evidence pertains only to adults. </p> </section> <section id="CD003328-sec-0007"> <h3 class="title" id="CD003328-sec-0007">Authors' conclusions</h3> <p>These results highlight the paucity of randomised clinical trials comparing different interventions for paracetamol overdose and their routes of administration and the low or very low level quality of the evidence that is available. Evidence from a single trial found activated charcoal seemed the best choice to reduce absorption of paracetamol. Acetylcysteine should be given to people at risk of toxicity including people presenting with liver failure. Further randomised clinical trials with low risk of bias and adequate number of participants are required to determine which regimen results in the fewest adverse effects with the best efficacy. Current management of paracetamol poisoning worldwide involves the administration of intravenous or oral acetylcysteine which is based mainly on observational studies. Results from these observational studies indicate that treatment with acetylcysteine seems to result in a decrease in morbidity and mortality, However, further evidence from randomised clinical trials comparing different treatments are needed. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003328-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003328-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003328-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003328-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003328-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD003328-abs-0007">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003328-abs-0005">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD003328-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD003328-abs-0010">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003328-abs-0014">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003328-abs-0003" lang="en"> <h3>Interventions for paracetamol (acetaminophen) overdose</h3> <p><b>Review question:</b> in this review, we looked at the evidence for the interventions (treatments) used to treat people with paracetamol (acetaminophen) poisoning. Mainly, we tried to assess what effects the interventions had on the number of deaths and the need for a liver transplant. </p> <p><b>Background:</b> paracetamol is one of the most common drugs taken in overdose. Intentional or accidental poisoning with paracetamol is a common cause of liver injury. </p> <p><b>Search date:</b> the evidence is current to January 2017. </p> <p><b>Study characteristics:</b> randomised clinical trials (studies where people are randomly put into one of two or more treatment groups) where participants had come to medical attention because they had taken a paracetamol overdose, intentionally or by accident, regardless of the amount of paracetamol taken or the age, sex, or other medical conditions of the person involved. </p> <p>There are many different interventions that can be used to try to treat people with paracetamol poisoning. These interventions include decreasing the absorption of the paracetamol ingested and hence decreasing the amount absorbed into the bloodstream. The agents include activated charcoal (that binds paracetamol together in the stomach), gastric lavage (stomach washout to remove as much paracetamol as possible), or ipecacuanha (a syrup that is swallowed and causes vomiting (being sick)). Paracetamol once absorbed into the bloodstream goes to the liver where the majority is broken down to harmless products. However, a small amount of the medicine is converted into a toxic product that the liver can normally handle but, when large amounts of paracetamol are taken, the liver is overwhelmed. As a consequence, the toxic product can damage the liver leading to liver failure, kidney failure, and in some cases death. Other interventions to treat paracetamol poisoning include medicines (antidotes) that may decrease the amount of the toxic products (such as a medicine called cimetidine) or breakdown the toxic products (including medicines called methionine, cysteamine, dimercaprol, or acetylcysteine). Finally, attempts can be made to remove paracetamol and its toxic products from the bloodstream using special blood cleansing equipment. All these treatments were examined. </p> <p>We found 11 randomised clinical trials with 700 participants. Most of these trials looked at different treatments. </p> <p><b>Key results:</b> activated charcoal, gastric lavage, and ipecacuanha may reduce absorption of paracetamol if started within one to two hours of paracetamol ingestion, but the clinical benefit was unclear. Activated charcoal seems to be the best choice if the person is able to take it. People may not be able to take charcoal if they are drowsy and some may dislike its taste or texture (or both). </p> <p>Of the treatments that remove the toxic products of paracetamol, acetylcysteine seems to reduce the rate of liver injury from paracetamol poisoning. Furthermore, it has fewer side effects than some other antidotes such as dimercaprol and cysteamine; its superiority to methionine was unclear. Acetylcysteine should be given to people with paracetamol poisoning at risk of liver damage, risk is determined by the dose ingested, time of ingestion, and investigations. </p> <p>More recent clinical trials have looked at ways to decrease side effects of intravenous (into a vein) acetylcysteine treatment, by altering the way it is given. These trials have shown that by using a slower infusion and lower initial dose of acetylcysteine, the proportion of side effects such as nausea (feeling sick) and vomiting, and allergy (the body's bad reaction to the medicine such as a rash) may be lowered. </p> <p><b>Quality of the evidence:</b> this review of interventions for paracetamol poisoning found surprisingly few published randomised clinical trials for this very common condition. Furthermore, the majority of trials had few participants and all were at high risk of bias. Accordingly, the quality of the evidence should be considered as low or very low. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003328-sec-0121" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003328-sec-0121"></div> <h3 class="title" id="CD003328-sec-0122">Implications for practice</h3> <section id="CD003328-sec-0122"> <p>There are few randomised clinical trials for how to treat people with paracetamol overdose, and the quality of evidence is low or very low. Current practices are often based on observational studies. Current treatments seem to have resulted in a decrease in mortality; therefore, there is no reason to abandon current practices without further evidence. Current practices include the use of activated charcoal within one to two hours of ingestion to reduce the absorption of paracetamol and the administration of an antidote such as acetylcysteine (oral or intravenous) or methionine in people at risk of hepatotoxicity. Risk assessment in trials has generally been based on a potentially toxic ingested dose (paracetamol greater than 7.5 g to 10 g or 150 mg/kg bodyweight to 200 mg/kg bodyweight or more) or plasma paracetamol concentration above a chosen risk‐line or based on all people with abnormal liver biochemistry or fulminant hepatic failure after paracetamol overdose. Acetylcysteine can be administered intravenously or orally. Recent studies have focused on decreasing the reaction rates from intravenous acetylcysteine.Slowing the infusion rate may decrease the rate of adverse reactions, and further research is needed into whether these regimens are as efficient. </p> </section> <h3 class="title" id="CD003328-sec-0123">Implications for research</h3> <section id="CD003328-sec-0123"> <p>People with a paracetamol overdose need to be studied in large multicentre randomised clinical trials with adequate methodology and with relevant clinical outcomes. The substantial fall in mortality from paracetamol overdose since the introduction of acetylcysteine means that it is unlikely that it would be considered ethical to randomise people to this drug versus placebo or no intervention. However, more research is needed comparing different interventions and routes of administration. This review has identified a number of topics that need assessment in randomised clinical trials (e.g. acetylcysteine administered intravenously versus orally; acetylcysteine optimum dosing regimen; acetylcysteine versus methionine: activated charcoal versus no decontamination or other methods for reducing paracetamol absorption). Furthermore, adverse events in relation to the different interventions should be reported systematically. New randomised clinical trials should be designed according to SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) (<a href="http://www.spirit-statement.org/" target="_blank">www.spirit‐statement.org/</a>), registered before inception (<a href="http://www.icmje.org/clin_trialup.htm" target="_blank">www.icmje.org/clin_trialup.htm</a>), and reported according to the CONSORT guidelines (<a href="http://www.consort-statement.org" target="_blank">www.consort‐statement.org</a>), as well as with public sharing of depersonalised data to allow individual participant data meta‐analyses (<a href="./references#CD003328-bbs2-0123" title="SkoogM , SaarimäkiJM , GluudC , SheininM , ErlendssonK , AamdalS , et al. Transparency and Registration in Clinical Research in the Nordic Countries. Oslo (Norway): Nordic Trial Alliance, NordForsk, 2015. ">Skoog 2015</a>). Such new trials ought to stratify participants according to perceived risks of liver failure. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003328-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003328-sec-0029"></div> <div class="table" id="CD003328-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Methionine and supportive treatment compared with supportive treatment for paracetamol (acetaminophen) overdose</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Methionine and supportive treatment compared with supportive treatment (randomised trials) for paracetamol (acetaminophen) overdose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with paracetamol (acetaminophen) overdose<br/> <b>Settings:</b> UK<br/> <b>Intervention:</b> methionine and supportive treatment<br/> <b>Comparison:</b> supportive treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Supportive treatment </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Methionine and supportive treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 0.14</b><br/> (0.00 to 6.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>26<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The Trial Sequential Analysis‐adjusted CI could not be estimated due to the paucity of data. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/> (0 to 362) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hepatotoxicity</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.05</b><br/> (0.01 to 0.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>26<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>615 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000<br/> (16 to 459) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised clinical trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for risk of bias (concerns regarding randomisation sequence generation and allocation concealment probably compromised).<br/> <sup>2</sup>Downgraded two levels because of serious imprecision (due to small sample studied, low number of deaths, and wide confidence intervals).<br/> <sup>3</sup>Downgraded one level because of imprecision (due to small sample studied). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003328-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Cysteamine compared with no intervention for paracetamol (acetaminophen) overdose</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cysteamine compared with no intervention (randomised trials) for paracetamol (acetaminophen) overdose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with paracetamol (acetaminophen) overdose<br/> <b>Settings:</b> Royal Victoria Infirmary, Newcastle, UK<br/> <b>Intervention:</b> cysteamine<br/> <b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Cysteamine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 0.53</b><br/> (0.05 to 5.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>65<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000<br/> (3 to 252) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hepatotoxicity</b> (aspartate aminotransferase &gt; 1000 IU/L) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.09</b><br/> (0.02 to 0.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>65<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis‐adjusted CI ranged from 0.00 to 24.0.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>545 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 1000<br/> (23 to 290) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised clinical trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level because of risk of bias (method of randomisation had potential for bias and allocation concealment not specified).<br/> <sup>2</sup>Downgraded two levels because of serious imprecision (due to small sample studied, low number of deaths, and confidence intervals are wide).<br/> <sup>3</sup>Downgraded one level because of imprecision (due to small sample studied). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003328-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Cysteamine compared with dimercaprol for paracetamol (acetaminophen) overdose</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cysteamine compared with dimercaprol (randomised trials) for paracetamol (acetaminophen) overdose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with paracetamol (acetaminophen) overdose<br/> <b>Settings:</b> UK<br/> <b>Intervention:</b> cysteamine<br/> <b>Comparison:</b> dimercaprol </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Dimercaprol </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Cysteamine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 0.14</b><br/> (0.00 to 6.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>52<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/> (0 to 214) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean maximum alanine aminotransferase</b> (IU/L) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean maximum alanine aminotransferase (IU/L) in the dimercaprol was 754</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean maximum alanine aminotransferase (IU/L) in the cysteamine group was 722 (IU/L)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Difference ‐32.00 (95% CI ‐512.9 to 448.9). The difference between the 2 groups was not significant. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised clinical trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels because of serious imprecision (due to small sample studied, low number of deaths, and confidence intervals wide).<br/> <sup>2</sup>Downgraded one level because of risk of bias (method of randomisation by envelopes and allocation not concealed).<br/> <sup>3</sup>Downgraded one level because of imprecision (due to small sample studied). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003328-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Cysteamine compared with methionine (randomised trials) for paracetamol (acetaminophen) overdose</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cysteamine compared with methionine (randomised trials) for paracetamol (acetaminophen) overdose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with paracetamol (acetaminophen) overdose<br/> <b>Settings:</b> Newcastle (Royal Victoria Infirmary) and London (Guy's Hospital)<br/> <b>Intervention:</b> cysteamine<br/> <b>Comparison:</b> methionine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Methionine </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Cysteamine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hepatotoxicity</b> (aspartate aminotransferase &gt; 1000 U/L) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.92</b><br/> (0.05 to 16.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>71 per 1000<br/> (4 to 578) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised clinical trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level because of risk of bias (concerns regarding randomisation and allocation concealment not specified).<br/> <sup>2</sup>Downgraded two levels because of serious imprecision (due to small sample studied and low number of deaths).<br/> <sup>3</sup>Downgraded two levels because of serious imprecision (due to small sample studied and wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003328-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Standard intravenous acetylcysteine regimen (20.5 hour) compared with shorter intravenous acetylcysteine regimen (12 hour) for paracetamol (acetaminophen) overdose</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Standard intravenous acetylcysteine regimen (20.5 hours) compared with shorter (12 hours) protocol for paracetamol (acetaminophen) overdose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with paracetamol (acetaminophen) overdose<br/> <b>Settings:</b> 3 acute clinical units in the UK<br/> <b>Intervention:</b> standard intravenous acetylcysteine regimen (20.25 hours)<br/> <b>Comparison:</b> shorter (12 hours) modified protocol </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Standard intravenous acetylcysteine regimen (20.25 hours)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Shorter (12‐hour protocol)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>222<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hepatotoxicity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.67</b> </p> <p>(0.11 to 4.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>202</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> <p>(3 to 111)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Vomiting, retching, or antiemetics</b> from 0‐2 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.30</b> </p> <p>(0.17 to 0.53)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>217<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>651 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>359 per 1000<br/> (241 to 498) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Vomiting, retching, or antiemetics</b> 0‐12 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.40</b> </p> <p>(0.22 to 0.75)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>203<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>784 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>593 per 1000<br/> (444 to 732) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Anaphylactoid symptoms</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.39</b> </p> <p>(0.21 to 0.70)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>208<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>750 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>539 per 1000<br/> (387 to 677) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised clinical trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level because of indirectness (a large number of prospective participants excluded prior to randomisation: 1539 judged suitable for treatment, only 222 randomised).<br/> <sup>2</sup>Downgraded two levels because of very serious imprecision (due to small sample studied and no deaths).<br/> <sup>3</sup>Downgraded two levels because of very serious imprecision (due to small sample studied, small numbers who developed hepatotoxicity, and wide confidence intervals).<br/> <sup>4</sup>Downgraded one level because of imprecision (due to small sample studied). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003328-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Oral compared with intravenous acetylcysteine for paracetamol (acetaminophen) overdose</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral compared with intravenous acetylcysteine for paracetamol (acetaminophen) overdose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with paracetamol (acetaminophen) overdose<br/> <b>Settings:</b> Baharloo Hospital (Tehran)<br/> <b>Intervention:</b> oral acetylcysteine<br/> <b>Comparison:</b> intravenous acetylcysteine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Intravenous acetylcysteine </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Oral acetylcysteine </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>66<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hepatotoxicity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rates of hepatotoxicity not reported, only mean alanine aminotransferase between the 2 study groups. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nausea</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 2.71</b><br/> (1.00 to 7.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>66<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>333 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>575 per 1000<br/> (333 to 787) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Vomiting</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 2.10</b><br/> (0.62 to 7.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>66<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>152 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>273 per 1000<br/> (100 to 560) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised clinical trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level because of risk of bias (due to randomisation details or concealment allocation were not specified, participants were excluded from IV group if they developed an anaphylactoid reaction unresponsive to decreasing the administration rate. Unclear whether these participants were analysed and should have been included as intention‐to‐treat).<br/> <sup>2</sup>Downgraded one level because of risk of imprecision (due to small sample studied).<br/> <sup>3</sup>Downgraded one level because of indirectness (amount of paracetamol ingested mean dose of 160 mg/kg to 170 mg/kg is below the toxic dose that often requires treatment). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003328-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Intravenous acetylcysteine compared with placebo in people with fulminant hepatic failure for paracetamol (acetaminophen) overdose</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous acetylcysteine compared with placebo in people with fulminant hepatic failure (randomised trials) for paracetamol (acetaminophen) overdose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with fulminant hepatic failure secondary to paracetamol (acetaminophen) overdose<br/> <b>Settings:</b> Liver Failure Unit, King's College Hospital <br/> <b>Intervention:</b> intravenous acetylcysteine<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Intravenous acetylcysteine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 0.29</b><br/> (0.09 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis‐adjusted CI ranged from 0.01 to 15.8.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>800 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>537 per 1000<br/> (265 to 790) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised clinical trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level because of risk of bias (randomisation and allocation concealment unclear).<br/> <sup>2</sup>Downgraded one level because of imprecision (small sample studied). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003328-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Initial infusion rate of intravenous acetylcysteine over 15 minutes compared with 60 minutes for paracetamol (acetaminophen) overdose</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Initial infusion rate of intravenous acetylcysteine over 15 minutes compared with 60 minutes (randomised trials) for paracetamol (acetaminophen) overdose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with paracetamol (acetaminophen) overdose<br/> <b>Settings:</b> multicentre study conducted in tertiary referral hospitals in Australia<br/> <b>Intervention:</b> initial infusion of acetylcysteine over 15 minutes<br/> <b>Comparison:</b> initial infusion of acetylcysteine over 60 minutes </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Initial infusion over 15 minutes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Initial infusion over 60 minutes</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>180<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hepatotoxicity</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.34</b> </p> <p>(0.39 to 4.56)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000<br/> (23 to 213) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Any adverse event</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.51</b> </p> <p>(0.27 to 0.96)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>180<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis‐adjusted CI ranged from 0.36 to 11.0.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>752 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>608 per 1000<br/> (451 to 745) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised clinical trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level because of risk of bias (possible bias due to method of randomisation via "randomisation slips" in a "closed box," many participants lost to follow‐up, and uneven numbers between the 2 treatment groups with many more participants in the 15‐minute infusion group).<br/> <sup>2</sup>Downgraded two levels because of serious imprecision (due to small sample studied and no deaths).<br/> <sup>3</sup>Downgraded two levels because of serious imprecision (due to small sample studied, low rate of hepatotoxicity, and wide confidence intervals).<br/> <sup>4</sup>Downgraded one level because of imprecision (due to small sample). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003328-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Oral plus intravenous acetylcysteine compared with intravenous acetylcysteine for paracetamol (acetaminophen) overdose</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral and intravenous acetylcysteine compared with intravenous acetylcysteine for paracetamol (acetaminophen) overdose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with paracetamol (acetaminophen) overdose<br/> <b>Settings:</b> poisoning referral centre in Iran<br/> <b>Intervention:</b> oral and intravenous acetylcysteine<br/> <b>Comparison:</b> intravenous acetylcysteine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Intravenous acetylcysteine </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Oral and intravenous acetylcysteine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Primary outcome for this study was anaphylactoid reaction.</p> <p>Unable to analyse these results due to large number excluded from one arm.<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hepatotoxicity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised clinical trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels because of serious risk of bias (randomisation sequence generation and allocation concealment not recorded, and a large number of participants excluded (10 excluded from the 25 randomised)).<br/> <sup>2</sup>Downgraded two levels because of serious imprecision (due to small sample studied and no deaths). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003328-tbl-0010"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Charcoal haemoperfusion compared with no intervention for paracetamol (acetaminophen) overdose</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Charcoal haemoperfusion compared with no intervention (randomised trials) for paracetamol (acetaminophen) overdose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with paracetamol (acetaminophen) overdose<br/> <b>Settings:</b> The Liver Unit, King's College Hospital, London UK<br/> <b>Intervention:</b> charcoal haemoperfusion<br/> <b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Charcoal haemoperfusion</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 7.39</b><br/> (0.15 to 372.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Note very small numbers in this trial; only 8 in each group.</p> <p>With only 1 death in the charcoal haemoperfusion arm.</p> <p>The Trial Sequential Analysis‐adjusted CI could not be calculated.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised clinical trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level because of risk of bias (randomisation sequence generation and allocation concealment not detailed).<br/> <sup>2</sup>Downgraded two levels because of serious imprecision (due to small sample studied and confidence intervals are very wide).<br/> <sup>3</sup>Downgraded one level because of risk of indirectness (imbalance between the two groups at baseline). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003328-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003328-sec-0030"></div> <p>Paracetamol (acetaminophen) is a mild analgesic and antipyretic agent which is commonly used worldwide (<a href="./references#CD003328-bbs2-0102" title="O'GradyJG . Paracetamol‐induced acute liver failure. Journal of Hepatology1997;26 (Suppl):41‐6. ">O'Grady 1997</a>). In therapeutic doses (for adults 500 mg to 1000 mg, three or four times per day), paracetamol has few adverse events (<a href="./references#CD003328-bbs2-0088" title="Koch‐WeserJ . Acetaminophen. New England Journal of Medicine1976;295(23):1297‐300. ">Koch‐Weser 1976</a>). During the late 1960s it was realised that paracetamol poisoning could result in severe hepatotoxicity, liver failure, renal failure, and death (<a href="./references#CD003328-bbs2-0062" title="DavidsonDG , EasthamWN . Acute liver necrosis following overdose of paracetamol. British Medical Journal1966;2(5512):497‐9. ">Davidson 1966</a>). Paracetamol is commonly taken in overdose either accidentally or intentionally (<a href="./references#CD003328-bbs2-0052" title="BuckleyN , EddlestonM . Paracetamol (acetaminophen) poisoning. BMJ Clinical Evidence2007;2007:2101. ">Buckley 2007</a>), and in many countries, it is the most common single compound taken in overdose (<a href="./references#CD003328-bbs2-0109" title="PrescottK , StrattonR , FreyerA , HallI , LeJeuneI . Detailed analyses of self‐poisoning episodes presenting to a large regional teaching hospital in the UK. British Journal of Clinical Pharmacology2009;68(2):260‐8. ">Prescott 2009</a>). In general, a single dose of more than 10 g or 150 mg/kg to 200 mg/kg of paracetamol carries a risk of liver damage (<a href="./references#CD003328-bbs2-0051" title="BuckleyNA , WhyteIM , O'ConnellDL , DawsonAH . Activated charcoal reduces the need for N‐acetylcysteine treatment after acetaminophen (paracetamol) overdose. Journal of Toxicology. Clinical Toxicology1999;37(6):753‐7. ">Buckley 1999a</a>), but smaller doses may also cause liver damage (<a href="./references#CD003328-bbs2-0090" title="KwanD , BartleWR , WalkerSE . Abnormal serum transaminases following therapeutic doses of acetaminophen in the absence of known risk factors. Digestive Diseases and Sciences1995;40(9):1951‐5. ">Kwan 1995</a>), particularly in people with chronic alcohol abuse or anorexia. Paracetamol toxicity is the leading cause of acute liver failure in many high‐income countries (<a href="./references#CD003328-bbs2-0091" title="LeeWM . Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. Hepatology (Baltimore, Md.)2004;40(1):6‐9. [MEDLINE: PMID: 15239078] ">Lee 2004</a>; <a href="./references#CD003328-bbs2-0101" title="MorganO , GriffithsC , MajeedA . Impact of paracetamol pack size restrictions on poisoning from paracetamol in England and Wales: an observational study. Journal of Public Health2005;27(1):19‐24. [MEDLINE: PMID: 15637104] ">Morgan 2005</a>; <a href="./references#CD003328-bbs2-0047" title="BernalW , HyyrylainenA , GeraA , AudimoolamVK , McPhailMJW , AuzingerG , et al. Lessons from look‐back in acute liver failure? A single centre experience of 3300 patients. Journal of Hepatology2013;59:74‐80. ">Bernal 2013</a>). One large prospective observational cohort study of 31 liver disease and transplant centres in the US, enrolling 2070 participants with acute liver failure between 1998 and 2013, found that paracetamol poisoning was the cause in half of the participants (<a href="./references#CD003328-bbs2-0110" title="ReubenA , TillmanH , FontanaRJ , DavernT , McGuireB , StravitzRT , et al. Outcomes in adults with acute liver failure between 1998 and 2013: an observational cohort study. Annals of Internal Medicine2016;164(11):724‐32. ">Reuben 2016</a>). </p> <p>It was not until the 1970s that several antidotes that replenish glutathione and detoxify <i>N</i> ‐acetyl‐<i>p</i>‐benzoquinone imine (NAPQI) were developed; these included methionine, cysteine, cysteamine, and dimercaprol (<a href="./references#CD003328-bbs2-0106" title="PrescottLF , SutherlandGR , ParkJ , SmithIJ , ProudfootAT . Cysteamine, methionine, and penicillamine in the treatment of paracetamol poisoning. Lancet1976;2(7977):109‐13. ">Prescott 1976</a>). Oral methionine and intravenous acetylcysteine have been used as antidotes in the UK from this time onwards (<a href="./references#CD003328-bbs2-0097" title="McElhattonPR , SullivanFM , VolansGN . Paracetamol overdose in pregnancy analysis of the outcomes of 300 cases referred to the Teratology Information Service. Reproductive Toxicology (Elmsford, N.Y.)1997;11(1):85‐94. ">McElhatton 1997</a>). In one observational study from Edinburgh, intravenous acetylcysteine first‐line was claimed to be equally as effective as cysteamine and methionine and free of adverse effects (<a href="./references#CD003328-bbs2-0107" title="PrescottLF , IllinngworthRN , ChrichleyJAJ , StewartMJ , AdamRD , ProudfootAT . Intravenous N‐acetylcysteine: the treatment of choice for paracetamol poisoning. British Medical Journal1979;2:1097‐100. ">Prescott 1979</a>). Ever since, acetylcysteine has been accepted as an antidote for paracetamol overdose either intravenously or orally. Much of the evidence for its use and efficacy comes from observational studies. Acetylcysteine has now become the mainstay and standard treatment for paracetamol poisoning and can either be administered as a 20‐ to 21‐hour intravenous acetylcysteine regimen or an oral acetylcysteine regimen (<a href="./references#CD003328-bbs2-0125" title="SmilksteinMJ , BronsteinAC , LindenC , AugensteinWL , KuligKW , RumackBH . Acetaminophen overdose: a 48‐hour intravenous N‐acetylcysteine treatment protocol. Annals of Emergency Medicine1991;20(10):1058‐63. ">Smilkstein 1991</a>; <a href="./references#CD003328-bbs2-0139" title="WooOF , MuellerPD , OlsonKR , AndersonIB , KimSY . Shorter duration of oral N‐acetylcysteine therapy for acute acetaminophen overdose. Annals of Emergency Medicine2000;35(4):363‐8. ">Woo 2000</a>; <a href="./references#CD003328-bbs2-0137" title="WilliamsonK , WahlMS , MycykMB . Direct comparison of 20‐hour IV, 36‐hour oral, and 72‐hour oral acetylcysteine for treatment of acute acetaminophen poisoning. American Journal of Therapeutics2013;20(1):37‐40. ">Williamson 2013</a>). </p> <p>Before acetylcysteine treatment was available, morbidity following paracetamol overdose was significant. In people with an initial paracetamol concentration above the probable risk nomogram line (200 mg/L at four hours), the reported mortality of untreated people was 5% (<a href="./references#CD003328-bbs2-0107" title="PrescottLF , IllinngworthRN , ChrichleyJAJ , StewartMJ , AdamRD , ProudfootAT . Intravenous N‐acetylcysteine: the treatment of choice for paracetamol poisoning. British Medical Journal1979;2:1097‐100. ">Prescott 1979</a>). This rate fell to 0.4% after the introduction of acetylcysteine (<a href="./references#CD003328-bbs2-0073" title="GunnellD , HawtonK , MurrayV , GarnierR , BismuthC , FaggJ , et al. Use of paracetamol for suicide and non‐fatal poisoning in the UK and France: are restrictions on availability justified?. Journal of Epidemiology and Community Health1997;51:175‐9. ">Gunnell 1997</a>). Furthermore, the previous Cochrane systematic review of acetylcysteine observational studies found acute liver injury in 58% of people who received no antidote. This decreased to 7% if acetylcysteine was administered within 10 hours of ingestion and 27% if administered beyond 10 hours (<a href="./references#CD003328-bbs2-0144" title="BrokJ , BuckleyN , GluudC . Interventions for paracetamol (acetaminophen) overdose. Cochrane Database of Systematic Reviews2006, Issue 2. [; DOI: 10.1002/14651858.CD003328.pub2; JC‐‐NLM: Journal ID:100909747] ">Brok 2006</a>). One systematic review of oral and intravenous acetylcysteine treatment following paracetamol poisoning from 1966 to 2009 found similar findings with late (greater than eight to 10 hours) acetylcysteine treatment associated with increased rates of hepatotoxicity (postbaseline aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level above 1000 IU/L) (<a href="./references#CD003328-bbs2-0072" title="GreenJL , HeardKJ , ReynoldsKM , AlbertD . Oral and intravenous acetylcysteine for treatment of acetaminophen toxicity: a systematic review and meta‐analysis. Western Journal of Emergency Medicine2013;14(3):218‐26. ">Green 2013</a>). Green and colleagues included 5164 participants with paracetamol poisoning (definition varied according to the study) in their meta‐analysis; they also compared intravenous and oral acetylcysteine. Rates of hepatotoxicity were similar in both groups at 5% to 6% with early treatment (within eight to 10 hours postingestion) and increasing to 23% to 26% if treatment was given beyond this time. </p> <p>Observational studies of acetylcysteine since the last Cochrane Review and meta‐analysis by Green and colleagues show very similar results with higher rates of hepatotoxicity in people treated more than eight hours postingestion (<a href="./references#CD003328-bbs2-0066" title="DuffullSB , IsbisterGK . Predicting the requirement for N‐acetylcysteine in paracetamol poisoning from reported dose. Clinical Toxicology (Philadelphia, Pa.)2013;51(8):772‐6. ">Duffull 2013</a>; <a href="./references#CD003328-bbs2-0096" title="MarksDJB , DarganPI , ArcherJRH , DaviesCL , DinesAM , WoodDM , et al. Outcomes from massive paracetamol overdose: a retrospective observational study. British Journal of Clinical Pharmacology2017;83:1163‐5. ">Marks 2017</a>). More recently, observational studies have found an increased risk of acute liver injury despite early treatment in people with higher plasma paracetamol concentrations at admission. This relationship persists even in people treated within eight hours of acetylcysteine (<a href="./references#CD003328-bbs2-0053" title="CairneyDG , BeckwithHK , Al‐HouraniK , EddlestonM , BatemanDN , DearJW . Plasma paracetamol concentration at hospital presentation has a dose‐dependent relationship with liver injury despite prompt treatment with intravenous acetylcysteine. Clinical Toxicology (Philadelphia, Pa.)2016;54(5):405‐10. ">Cairney 2016</a>; <a href="./references#CD003328-bbs2-0056" title="ChiewAL , IsbisterGK , KirbyKA , PageCB , ChanBSH , BuckleyNA . Massive paracetamol overdose: an observational study of the effect of activated charcoal and increased acetylcysteine dose (ATOM‐2). Clinical Toxicology (Philadelphia, Pa.)2017;55(10):1055‐65. ">Chiew 2017</a>; <a href="./references#CD003328-bbs2-0096" title="MarksDJB , DarganPI , ArcherJRH , DaviesCL , DinesAM , WoodDM , et al. Outcomes from massive paracetamol overdose: a retrospective observational study. British Journal of Clinical Pharmacology2017;83:1163‐5. ">Marks 2017</a>). In these observational studies, deaths were uncommon and remained at less than 1%. Observational acetylcysteine studies continue to show low rates of acute liver injury particularly in people treated early. The rate of liver injury and death has improved from historical patient series of no antidote and this has meant randomised clinical trials assessing acetylcysteine versus no treatment have not been considered feasible. Instead, trials have focused on different acetylcysteine regimens dose or duration (or both) to examine the optimal way of administering acetylcysteine. Previous versions of this review have also included and examined observational studies. In this updated review, we excluded observational studies. In the last review and since, nearly all observational studies have examined outcomes with one treatment arm and no comparison groups. Hence, further analysis of observational studies adds little to evidence from previous reviews on treatment effectiveness or comparative effectiveness. </p> <p>While methionine has fallen out of use in Western countries, it remains on the World Health Organization (WHO) essential drug list, a position that was reviewed and affirmed in 2011 (<a href="./references#CD003328-bbs2-0122" title="ShiagoK , WatsonI , ReidenbergMM . Application to change the status of methionine or N‐acetylcysteine on the model list, 2011. www.who.int/selection_medicines/committees/expert/18/applications/Delete_Methionine.pdf (accessed 20 May 2016). ">Shiago 2011</a>). In 1984, the therapeutic guidelines in the <i>British Medical Journal</i> regarded methionine and acetylcysteine as equally effective (<a href="./references#CD003328-bbs2-0079" title="HenryJ , VolansG . ABC of poisoning. Analgesics: II ‐ paracetamol. British Medical Journal (Clinical Research Ed.)1984;289(6449):907‐8. ">Henry 1984</a>). The 2011 WHO panel review of the evidence concluded that acetylcysteine and methionine had equal efficacy and safety (and specifically that there was no evidence against this proposition), and thus, the cheaper methionine was the most cost‐effective antidote. Hence, it is widely used in low‐ to middle‐income countries such as Sri Lanka (<a href="./references#CD003328-bbs2-0121" title="SenarathnaSG , SriRS , BuckleyN , FernandopulleR . A cost effectiveness analysis of the preferred antidotes for acute paracetamol poisoning patients in Sri Lanka. BMC Clinical Pharmacology2012;12(1):6. ">Senarathna 2012</a>). </p> <p>Activated charcoal is a mode of decontamination often used in the management of people who have overdosed. Multiple observational and volunteer studies have investigated the effect of charcoal on paracetamol absorption (<a href="./references#CD003328-bbs2-0051" title="BuckleyNA , WhyteIM , O'ConnellDL , DawsonAH . Activated charcoal reduces the need for N‐acetylcysteine treatment after acetaminophen (paracetamol) overdose. Journal of Toxicology. Clinical Toxicology1999;37(6):753‐7. ">Buckley 1999a</a>; <a href="./references#CD003328-bbs2-0141" title="YeatesPJA , ThomasSHL . Effectiveness of delayed activated charcoal administration in simulated paracetamol (acetaminophen) overdose. British Journal of Clinical Pharmacology2000;49(1):11‐4. ">Yeates 2000</a>). Buckley and colleagues, in one observational study of 981 participants, found that people receiving activated charcoal within two hours of ingestion were less likely to have a toxic paracetamol concentration. In people receiving activated charcoal within two hours, 15% had a paracetamol concentration above 150 mg/L at the four‐hour nomogram treatment line compared to 41% having a level above the same line who did not receive activated charcoal (<a href="./references#CD003328-bbs2-0051" title="BuckleyNA , WhyteIM , O'ConnellDL , DawsonAH . Activated charcoal reduces the need for N‐acetylcysteine treatment after acetaminophen (paracetamol) overdose. Journal of Toxicology. Clinical Toxicology1999;37(6):753‐7. ">Buckley 1999a</a>). Similarly, Duffull and colleagues, in one observational study of 1571 people with acute paracetamol poisoning found that those receiving activated charcoal had a reduced probability of having a paracetamol concentration above 150 mg/L at the four‐hour nomogram line (<a href="./references#CD003328-bbs2-0066" title="DuffullSB , IsbisterGK . Predicting the requirement for N‐acetylcysteine in paracetamol poisoning from reported dose. Clinical Toxicology (Philadelphia, Pa.)2013;51(8):772‐6. ">Duffull 2013</a>). One observational series of 200 participants ingesting greater than 40 g of paracetamol found paracetamol concentrations were markedly reduced in those receiving activated charcoal within four hours and a probable benefit of reducing the risk of hepatotoxicity (ALT greater than 1000 U/L) (<a href="./references#CD003328-bbs2-0056" title="ChiewAL , IsbisterGK , KirbyKA , PageCB , ChanBSH , BuckleyNA . Massive paracetamol overdose: an observational study of the effect of activated charcoal and increased acetylcysteine dose (ATOM‐2). Clinical Toxicology (Philadelphia, Pa.)2017;55(10):1055‐65. ">Chiew 2017</a>). Healthy volunteer studies similarly showed a reduction in paracetamol absorption when activated charcoal was administered within two hours of ingestion (<a href="./references#CD003328-bbs2-0141" title="YeatesPJA , ThomasSHL . Effectiveness of delayed activated charcoal administration in simulated paracetamol (acetaminophen) overdose. British Journal of Clinical Pharmacology2000;49(1):11‐4. ">Yeates 2000</a>; <a href="./references#CD003328-bbs2-0071" title="GreenR , GriersonR , SitarDS , TenenbbeinM . How long after drug ingestion is activated charcoal still effective?. Journal of Toxicology. Clinical Toxicology2001;39(6):601‐5. ">Green 2001</a>; <a href="./references#CD003328-bbs2-0057" title="ChristophersenAB , LevinD , HoegbergLCG , AngeloHR , KampmannJP . Activated charcoal alone or after gastric lavage: a simulated large paracetamol intoxication. British Journal of Clinical Pharmacology2002;53:312‐7. ">Christophersen 2002</a>). </p> <p>Paracetamol poisoning treatment protocols vary worldwide (<a href="./references#CD003328-bbs2-0138" title="WolfSJ , HeardK , SloanEP , JagodaAS . Clinical policy: critical issues in the management of patients presenting to the emergency department with acetaminophen overdose. Annals of Emergency Medicine2007;50:292‐313. ">Wolf 2007</a>; <a href="./references#CD003328-bbs2-0098" title="Medicines and Healthcare products Regulatory Agency. Treating paracetamol overdose with intravenous acetylcysteine: new guidance, 2012. www.gov.uk/drug‐safety‐update/treating‐paracetamol‐overdose‐with‐intravenous‐acetylcysteine‐new‐guidance (accessed 20 May 2016). ">MHPRA 2012</a>; <a href="./references#CD003328-bbs2-0054" title="ChiewAL , FountainJS , GraudinsA , IsbisterGK , ReithD , BuckleyNA . Summary statement: new guidelines for the management of paracetamol poisoning in Australia and New Zealand. Medical Journal of Australia2015;203(5):215‐8. ">Chiew 2015</a>; <a href="./references#CD003328-bbs2-0078" title="HeardK , NewtonA . Paracetamol overdose. BMJ Best Practice: bestpractice.bmj.com last updated: 28 March 2017:1‐46. ">Heard 2017</a>). People are unlikely to develop hepatotoxicity if they have ingested less than 150 mg/kg to 200 mg/kg of paracetamol (<a href="./references#CD003328-bbs2-0132" title="ValeJA , KuligK , American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists. Position statement: gastric lavage. Journal of Toxicology. Clinical Toxicology2004;42(7):933‐43. [MEDLINE: PMID: 15641639] ">Vale 2004</a>; <a href="./references#CD003328-bbs2-0061" title="DartR , ErdmanA , OlsonK , ChristiansonG , ManoguerraA , ChykaP , et al. Acetaminophen poisoning: an evidence‐based consensus guideline for out‐of‐hospital management. Clinical Toxicology2006;44(1):1‐18. [] ">Dart 2006</a>), or 10 g of paracetamol (whichever is less) (<a href="./references#CD003328-bbs2-0051" title="BuckleyNA , WhyteIM , O'ConnellDL , DawsonAH . Activated charcoal reduces the need for N‐acetylcysteine treatment after acetaminophen (paracetamol) overdose. Journal of Toxicology. Clinical Toxicology1999;37(6):753‐7. ">Buckley 1999a</a>), unless people have other risk factors such as chronic ethanol abuse or anorexia. A prediction of a person's risk based on reported dose of paracetamol may be limited as they or their relatives are often unaware of the exact amount ingested and the exact timing. The decision to treat a person with acute paracetamol ingestion with either acetylcysteine or methionine is usually based on their paracetamol concentration taken at a known time since ingestion. This concentration is plotted on a paracetamol nomogram such as the Rumack‐Matthew nomogram, to determine the need for treatment (<a href="./references#CD003328-bbs2-0124" title="SmilksteinMJ , KnappGL , KuligKW , RumackBH . Efficacy of oral N‐acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). New England Journal of Medicine1988;319(24):1557‐62. ">Smilkstein 1988</a>). Plotting paracetamol concentration versus time since ingestion, there are various 'treatment lines' and 'risk lines' for developing hepatotoxicity that are utilised to guide treatment. These 'nomograms' lines are sometimes referred to as the high risk (300 line; i.e. a line commencing from a paracetamol concentration of 300 mg/L at four hours postingestion), the probable risk (200 line), and the possible risk (150 line) used to guide treatment in such countries as Canada, Australia, New Zealand, and the US (<a href="./references#CD003328-bbs2-0113" title="RumackBH , MatthewH . Acetaminophen poisoning and toxicity. Pediatrics1975;55:871‐6. ">Rumack 1975</a>; <a href="./references#CD003328-bbs2-0107" title="PrescottLF , IllinngworthRN , ChrichleyJAJ , StewartMJ , AdamRD , ProudfootAT . Intravenous N‐acetylcysteine: the treatment of choice for paracetamol poisoning. British Medical Journal1979;2:1097‐100. ">Prescott 1979</a>; <a href="./references#CD003328-bbs2-0125" title="SmilksteinMJ , BronsteinAC , LindenC , AugensteinWL , KuligKW , RumackBH . Acetaminophen overdose: a 48‐hour intravenous N‐acetylcysteine treatment protocol. Annals of Emergency Medicine1991;20(10):1058‐63. ">Smilkstein 1991</a>; <a href="./references#CD003328-bbs2-0060" title="DalyFF , FountainJS , MurrayL , GraudinsA , BuckleyNA , Panel of Australian and New Zealand clinical toxicologists. Guidelines for the management of paracetamol poisoning in Australia and New Zealand ‐ explanation and elaboration. A consensus statement from clinical toxicologists consulting to the Australasian poisons information centres. Medical Journal of Australia2008;188(5):296‐301. ">Daly 2008</a>). In the UK in 2012, the treatment line was lowered further to the 100 mg/L (660 μmol/L) line (<a href="./references#CD003328-bbs2-0098" title="Medicines and Healthcare products Regulatory Agency. Treating paracetamol overdose with intravenous acetylcysteine: new guidance, 2012. www.gov.uk/drug‐safety‐update/treating‐paracetamol‐overdose‐with‐intravenous‐acetylcysteine‐new‐guidance (accessed 20 May 2016). ">MHPRA 2012</a>). However, other countries do not utilise these nomograms and treat all people with acute paracetamol ingestion with acetylcysteine (<a href="./references#CD003328-bbs2-0118" title="SchmidtLE , DalhoffK . Risk factors in the development of adverse reactions to N‐acetylcysteine in patients with paracetamol poisoning. British Journal of Pharmacology2001;51(1):87‐91. ">Schmidt 2001</a>). If the time of ingestion is unknown, or the treating doctor is not confident of the history of ingestion, or if a paracetamol concentration is not available or not used, treatment with acetylcysteine is commenced (<a href="./references#CD003328-bbs2-0061" title="DartR , ErdmanA , OlsonK , ChristiansonG , ManoguerraA , ChykaP , et al. Acetaminophen poisoning: an evidence‐based consensus guideline for out‐of‐hospital management. Clinical Toxicology2006;44(1):1‐18. [] ">Dart 2006</a>; <a href="./references#CD003328-bbs2-0060" title="DalyFF , FountainJS , MurrayL , GraudinsA , BuckleyNA , Panel of Australian and New Zealand clinical toxicologists. Guidelines for the management of paracetamol poisoning in Australia and New Zealand ‐ explanation and elaboration. A consensus statement from clinical toxicologists consulting to the Australasian poisons information centres. Medical Journal of Australia2008;188(5):296‐301. ">Daly 2008</a>). </p> <section id="CD003328-sec-0031"> <h3 class="title" id="CD003328-sec-0031">Description of the condition</h3> <p>Paracetamol overdose prior to the 1970s was associated with significant morbidity and mortality. It is still the leading cause of acute liver failure in Western countries (<a href="./references#CD003328-bbs2-0047" title="BernalW , HyyrylainenA , GeraA , AudimoolamVK , McPhailMJW , AuzingerG , et al. Lessons from look‐back in acute liver failure? A single centre experience of 3300 patients. Journal of Hepatology2013;59:74‐80. ">Bernal 2013</a>). Paracetamol is extensively metabolised by the liver; in therapeutic doses in adults, the major non‐toxic metabolites are sulphate and glucuronide conjugates which account for 30% (sulphate) and 55% (glucuronide) of the metabolites. A highly reactive toxic metabolite NAPQI is formed by cytochrome P450 2E1; it is responsible for the hepatocellular injury that occurs when paracetamol is taken in excess (<a href="./references#CD003328-bbs2-0099" title="MitchellJR , ThorgeirrsonSS , PotterWZ . Acetaminophen induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clinical Pharmacology and Therapeutics1974;16(4):676‐84. [] ">Mitchell 1974</a>). The small amounts of NAPQI produced after therapeutic doses of paracetamol are detoxified by glutathione‐dependent reactions. However, in paracetamol overdose, the formation of NAPQI depletes glutathione; once glutathione is depleted to about one‐third of its normal level, NAPQI starts binding covalently to critical cellular proteins. It is hypothesised that this results in loss of activity and function of critical proteins and eventually hepatic cell death (<a href="./references#CD003328-bbs2-0099" title="MitchellJR , ThorgeirrsonSS , PotterWZ . Acetaminophen induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clinical Pharmacology and Therapeutics1974;16(4):676‐84. [] ">Mitchell 1974</a>). </p> </section> <section id="CD003328-sec-0032"> <h3 class="title" id="CD003328-sec-0032">Description of the intervention</h3> <p>Many different types of interventions are used to treat paracetamol overdose. These interventions include: </p> <p> <ul id="CD003328-list-0001"> <li> <p>those that decrease paracetamol absorption from the gastrointestinal tract, including gastric lavage, activated charcoal, and ipecacuanha (ipecac syrup, an emetic); </p> </li> <li> <p>antidotes that prevent the conversion of paracetamol to its hepatotoxic metabolite NAPQI, such as cimetidine; </p> </li> <li> <p>antidotes to detoxify NAPQI, such as methionine, cysteine, cysteamine, dimercaprol, or acetylcysteine; </p> </li> <li> <p>those that remove paracetamol from the blood after the drug has entered the bloodstream. This includes intermittent haemodialysis, intermittent haemoperfusion, continuous renal replacement modalities, or charcoal haemoperfusion. </p> </li> </ul> </p> </section> <section id="CD003328-sec-0033"> <h3 class="title" id="CD003328-sec-0033">How the intervention might work</h3> <p>There are many different interventions that can be utilised to manage a person with paracetamol poisoning. These interventions work in different ways. First, there are interventions to reduce the absorption of paracetamol once ingested (decontamination), either by binding paracetamol to activated charcoal or removing paracetamol from the stomach by gastric lavage or ipecac syrup (forcing the person to vomit) (<a href="./references#CD003328-bbs2-0011" title="UnderhillTJ , GreeneMK , DoveAF . A comparison of the efficacy of gastric lavage, ipecacuanha and activated charcoal in the emergency management of paracetamol overdose. Archives of Emergency Medicine1990;7:148‐54. ">Underhill 1990</a>; <a href="./references#CD003328-bbs2-0051" title="BuckleyNA , WhyteIM , O'ConnellDL , DawsonAH . Activated charcoal reduces the need for N‐acetylcysteine treatment after acetaminophen (paracetamol) overdose. Journal of Toxicology. Clinical Toxicology1999;37(6):753‐7. ">Buckley 1999a</a>). </p> <p>Once absorbed into the bloodstream, paracetamol can be removed from the blood, in cases of severe poisoning, with intermittent haemodialysis, intermittent haemoperfusion, continuous renal replacement modalities, or charcoal haemoperfusion (<a href="./references#CD003328-bbs2-0041" title="O'GradyJG , GimsonAE , O'BrienCJ , PucknellA , HughesRD , WilliamsR . Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology1988;94(5):1186‐92. ">O'Grady 1988</a>; <a href="./references#CD003328-bbs2-0080" title="HigginsRM , GoldsmithDJ , MacDiarmid‐GordonA , TabernerD , VenningMC , AckrillP . Treating paracetamol overdose by charcoal haemoperfusion and long‐hours high‐flux dialysis. QJM : Monthly Journal of the Association of Physicians1996;89(4):297‐306. ">Higgins 1996</a>; <a href="./references#CD003328-bbs2-0070" title="GosselinS , JuurlinkDN , KielsteinJT , GhannoumM , LavergneV , NolinTD , EXTRIP Workgroup. Extracorporeal treatment for acetaminophen poisoning: recommendations from the EXTRIP workgroup. Clinical Toxicology (Philadelphia, Pa.)2014;52(852):856‐67. ">Gosselin 2014</a>). </p> <p>Other treatment options are drugs such as cimetidine that work by inhibiting cytochrome P‐450. The enzyme cytochrome P‐450 breaks down paracetamol into the toxic metabolite NAPQI. By inhibiting cytochrome‐P450 this may reduce the production of NAPQI (<a href="./references#CD003328-bbs2-0126" title="SpeegKV , BayMK . Prevention and treatment of drug‐induced liver disease. Gastroenterology Clinics of North America1995;24(4):1047‐64. ">Speeg 1995</a>). </p> <p>Antidotes that detoxify NAPQI, work by replenishing glutathione, and hence preventing the toxic effects due to this metabolite. Several antidotes to NAPQI were developed in the 1970s, including methionine, cysteine, cysteamine, and dimercaprol (<a href="./references#CD003328-bbs2-0106" title="PrescottLF , SutherlandGR , ParkJ , SmithIJ , ProudfootAT . Cysteamine, methionine, and penicillamine in the treatment of paracetamol poisoning. Lancet1976;2(7977):109‐13. ">Prescott 1976</a>). The amino acid, cysteine, is the main factor limiting the synthesis of glutathione. Acetylcysteine is a cysteine precursor, that is hydrolysed intracellularly to cysteine, thus replenishing glutathione (<a href="./references#CD003328-bbs2-0103" title="OlssonB , JohanssonM , GabrielssonJ , BolmeP . Pharmacokinetics and bioavailability of reduced and oxidized N‐acetylcysteine. Journal of Clinical Pharmacology1988;34(1):77‐82. ">Olsson 1988</a>). Glutathione can then covalently bind NAPQI in a 1:1 ratio. NAPQI is then detoxified via irreversible glutathione conjugation to two non‐toxic metabolites, mercapturic acid and cysteine conjugates (<a href="./references#CD003328-bbs2-0108" title="PrescottLF . Kinetics and metabolism of paracetamol and phenacetin. British Journal of Clinical Pharmacology1980;10:291S‐8S. ">Prescott 1980</a>). Acetylcysteine also supplies thiol groups, which can directly react with NAPQI in hepatocytes (<a href="./references#CD003328-bbs2-0085" title="JonesAL . Mechanism of action and value of N acetylcysteine in the treatment of early and late acetaminophen poisoning: a critical review. Journal of Toxicology. Clinical Toxicology1998;36:277‐85. ">Jones 1998</a>). </p> </section> <section id="CD003328-sec-0034"> <h3 class="title" id="CD003328-sec-0034">Why it is important to do this review</h3> <p>Paracetamol overdose is common and is still a leading cause of acute liver failure in many countries. This updated systematic review aimed to assess the benefits and harms of interventions for paracetamol overdose. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003328-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003328-sec-0035"></div> <p>To assess the benefits and harms of interventions for paracetamol overdosage irrespective of the cause of the overdose. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003328-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003328-sec-0036"></div> <section id="CD003328-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003328-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included randomised clinical trials examining the benefits and harms of interventions for people with paracetamol overdose regardless of sources of publication and language. </p> </section> <section id="CD003328-sec-0039"> <h4 class="title">Types of participants</h4> <p>People who had ingested a paracetamol overdose. The definition of a paracetamol overdose was not clear‐cut and the risk depended on many factors such as age, weight, comorbidities, concomitant medication, and alcohol ingestion. Therefore, all trials on people with paracetamol poisoning were included irrespective of inclusion criteria applied in the trial (e.g. age, time to treatment, comorbidities, etc.). </p> </section> <section id="CD003328-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Intervention with gastric lavage, ipecacuanha, or activated charcoal at any dose or duration compared with placebo/no intervention or with each other. </p> <p>Intervention with antidotes (cimetidine, cysteamine, methionine, dimercaprol, and acetylcysteine) compared with each other, with placebo/no interventions, or other interventions for paracetamol overdose. </p> <p>Intervention with extracorporeal treatments such as charcoal haemoperfusion, intermittent haemodialysis, or continuous renal replacement therapy compared with placebo/no interventions or other interventions for paracetamol overdose. </p> <p>Different doses, durations, or method of administration (oral or intravenously) of acetylcysteine compared with each other. </p> <p>Cointerventions were allowed if received equally in all groups of the trial.</p> <p>We did not want to examine interventions for liver failure, for example different types of liver support systems, or interventions to treat secondary complications of liver failure such as hepatorenal failure, hepatic encephalopathy, coagulopathy, and cerebral oedema. Interventions for acute liver failure would benefit from being addressed in a separate review, with a subgroup analysis of people with paracetamol overdose. </p> </section> <section id="CD003328-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD003328-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003328-list-0002"> <li> <p>Mortality: all‐cause and liver‐related.</p> </li> <li> <p>Liver transplantation.</p> </li> </ul> </p> </section> <section id="CD003328-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003328-list-0003"> <li> <p>Acute hepatitis (elevation of the serum transaminases greater than three times the upper limit of normal (ULN)). </p> </li> <li> <p>Hepatotoxicity (most commonly defined as number of participants with serum AST or serum ALT greater than 1000 IU/L). </p> </li> <li> <p>Severe acute hepatitis: transaminitis plus an international normalised ratio (INR) greater than 2. </p> </li> <li> <p>Acute (fulminant) hepatic failure defined as development of hepatic encephalopathy on a background of severe acute hepatitis (elevation of the serum transaminases plus prolongation of the prothrombin time). </p> </li> <li> <p>Adverse events.</p> </li> <li> <p>Plasma paracetamol concentration (e.g. plasma paracetamol above a risk line (nomogram)), fall in plasma paracetamol versus time, absorption of paracetamol measured as area under the curve (AUC) of the plasma (or urine) concentration versus time curve. </p> </li> </ul> </p> </section> </section> </section> <section id="CD003328-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003328-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched The Cochrane Hepato‐Biliary Group Controlled Trials Register (<a href="./references#CD003328-bbs2-0069" title="GluudC , NikolovaD , KlingenbergSL . Cochrane Hepato‐Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2017, Issue 5. Art. No.: LIVER. ">Gluud 2017</a>; January 2017), Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (2016, Issue 11), MEDLINE Ovid (1946 to January 2017), Embase Ovid (1974 to January 2017), and Science Citation Index Expanded (Web of Science; 1900 to January 2017) (<a href="./references#CD003328-bbs2-0112" title="RoyleP , MilneR . Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care2003;19(4):591‐603. ">Royle 2003</a>). <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002041.pub3/full" target="_blank">Appendix 1</a> provides the search strategies and the time spans of the searches. </p> </section> <section id="CD003328-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We examined the reference lists of relevant papers identified by the search and other published reviews. We searched the WHO International Clinical Trials Registry Platform (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>), which includes (among others) the EU Clinical Trials Register and Australian New Zealand Clinical Trials Registry. We searched the ClinicalTrials.gov database, a service of the US National Institute of Health for trials (<a href="https://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>). </p> </section> </section> <section id="CD003328-sec-0047"> <h3 class="title" id="CD003328-sec-0047">Data collection and analysis</h3> <p>Two review authors (AC, NB) screened the electronic search results for possibly relevant trials and retrieved the full text. Two review authors (AC and NB) evaluated whether the trials fulfilled the inclusion criteria and extracted data. We resolved disagreements by discussion. We listed included trials (<a href="./references#CD003328-sec-0135" title="">Characteristics of included studies</a> table) and excluded trials (<a href="./references#CD003328-sec-0136" title="">Characteristics of excluded studies</a> table) with the reason for exclusion. We wrote to the principal investigator of included trials to ask for relevant data if such data were not presented in the published reports. </p> <section id="CD003328-sec-0048"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>As there were changes in the risk of bias domains since the last review, we reassessed all trials. Two review authors (AC and NB) independently assessed risk of bias of all included studies using Cochrane's tool for assessing domains for risk of bias (<a href="./references#CD003328-bbs2-0082" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org. ">Higgins 2011a</a>) according to The Cochrane Hepato‐Biliary Group Module (<a href="./references#CD003328-bbs2-0069" title="GluudC , NikolovaD , KlingenbergSL . Cochrane Hepato‐Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2017, Issue 5. Art. No.: LIVER. ">Gluud 2017</a>) and methodological studies (<a href="./references#CD003328-bbs2-0120" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. ">Schulz 1995</a>; <a href="./references#CD003328-bbs2-0100" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352(9128):609‐13. ">Moher 1998</a>; <a href="./references#CD003328-bbs2-0087" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. [PUBMED: 11730399] ">Kjaergard 2001</a>; <a href="./references#CD003328-bbs2-0140" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.)2008;336(7644):601‐5. [PUBMED: 18316340] ">Wood 2008</a>; <a href="./references#CD003328-bbs2-0116" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. [PUBMED: 22945832] ">Savović 2012a</a>; <a href="./references#CD003328-bbs2-0117" title="SavovićJ , JonesH , AltmanD , HarrisR , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta‐epidemiological studies. Health Technology Assessment2012;16(35):1‐82. [PUBMED: 22989478] ">Savović 2012b</a>; <a href="./references#CD003328-bbs2-0094" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3; PUBMED: 23235689] ">Lundh 2017</a>). We used the following definitions in the assessment of risk of bias. </p> <section id="CD003328-sec-0049"> <h5 class="title">Allocation sequence generation</h5> <p> <ul id="CD003328-list-0004"> <li> <p>Low risk of bias: sequence generation was achieved using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if performed by an independent person not otherwise involved in the trial. </p> </li> <li> <p>Unclear risk of bias: the method of sequence generation was not specified.</p> </li> <li> <p>High risk of bias: the sequence generation method was not randomised or only quasi‐randomised. We only used these studies for the assessments of harms and not for benefits. </p> </li> </ul> </p> </section> <section id="CD003328-sec-0050"> <h5 class="title">Allocation concealment</h5> <p> <ul id="CD003328-list-0005"> <li> <p>Low risk of bias: the participant allocations could not have been foreseen in advance of, or during, enrolment. Allocation was controlled by a central and independent randomisation unit, onsite locked computer, identically looking numbered sealed opaque envelopes, or drug bottles or containers prepared by an independent pharmacist or investigator. The allocation sequence was unknown to the investigators. </p> </li> <li> <p>Unclear risk of bias: the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment. </p> </li> <li> <p>High risk of bias: the allocation sequence was likely to be known to the investigators who assigned the participants. We only used these studies for the assessments of harms and not for benefits. </p> </li> </ul> </p> </section> <section id="CD003328-sec-0051"> <h5 class="title">Blinding of participants and treatment providers (performance bias)</h5> <p> <ul id="CD003328-list-0006"> <li> <p>Low risk of bias: it was mentioned that both participants and personnel providing the interventions were blinded and this was described. </p> </li> <li> <p>Unclear risk of bias: it was not mentioned if the trial was blinded, or the extent of blinding was insufficiently described. </p> </li> <li> <p>High risk of bias: no blinding or incomplete blinding was performed.</p> </li> </ul> </p> </section> <section id="CD003328-sec-0052"> <h5 class="title">Blinding of outcome assessment (detection bias)</h5> <p> <ul id="CD003328-list-0007"> <li> <p>Low risk of bias: it was mentioned that outcome assessors were blinded and this was described. </p> </li> <li> <p>Unclear risk of bias: it was not mentioned if the trial was blinded, or the extent of blinding was insufficiently described. </p> </li> <li> <p>High risk of bias: no blinding or incomplete blinding was performed.</p> </li> </ul> </p> </section> <section id="CD003328-sec-0053"> <h5 class="title">Incomplete outcome data</h5> <p> <ul id="CD003328-list-0008"> <li> <p>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. The study used sufficient methods, such as multiple imputation, to handle missing data. </p> </li> <li> <p>Unclear risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias on the results. </p> </li> <li> <p>High risk of bias: the results were likely to be biased due to missing data.</p> </li> </ul> </p> </section> <section id="CD003328-sec-0054"> <h5 class="title">Selective outcome reporting</h5> <p> <ul id="CD003328-list-0009"> <li> <p>Low risk of bias: a protocol was published before or at the time the trial was begun and the outcomes called for in the protocol were reported on. If there was no protocol or the protocol was published after the trial had begun, reporting of all‐cause mortality and serious adverse events granted the trial a grade of low risk of bias. </p> </li> <li> <p>Unclear risk of bias: no protocol was published and the outcomes all‐cause mortality and serious adverse events were not reported on. </p> </li> <li> <p>High risk of bias: the outcomes in the protocol were not reported on.</p> </li> </ul> </p> </section> <section id="CD003328-sec-0055"> <h5 class="title">For‐profit bias</h5> <p> <ul id="CD003328-list-0010"> <li> <p>Low risk of bias: the trial appeared to be free of industry sponsorship or other type of for‐profit support that may have manipulated the trial design, conductance, or results of the trial. </p> </li> <li> <p>Unclear risk of bias: the trial may or may not have been free of for‐profit bias as no information on clinical trial support or sponsorship was provided. </p> </li> <li> <p>High risk of bias: the trial was sponsored by industry or received other type of for‐profit support. </p> </li> </ul> </p> </section> <section id="CD003328-sec-0056"> <h5 class="title">Other bias</h5> <p> <ul id="CD003328-list-0011"> <li> <p>Low risk of bias: the trial appeared to be free of other bias domains (e.g. academic bias) that could put it at risk of bias. </p> </li> <li> <p>Unclear risk of bias: the trial may or may not have been free of other domains that could put it at risk of bias. </p> </li> <li> <p>High risk of bias: there were other factors in the trial that could have put it at risk of bias (e.g. authors had conducted trials on the same topic). </p> </li> </ul> </p> </section> <section id="CD003328-sec-0057"> <h5 class="title">Overall risk of bias</h5> <p>We judged trials to be at a low risk of bias if they were assessed as at a low risk of bias in all the above domains. We judged trials to be at a high risk of bias if they were assessed as having an unclear risk of bias or a high risk of bias in one or more of the above domains. We assessed the domains 'blinding of outcome assessment' and 'incomplete outcome data' for each outcome. Thus, we were able to assess the bias risk for each result in addition to each trial. The results of our primary outcomes with a low risk of bias should have been our primary analyses. </p> <p>Two review authors (AC and NB) independently assessed the risk of bias of each included trial against these criteria. Review authors were not blinded with respect to trial authors, institution, or journal. The authors resolved disagreements by consensus, with a third review author (CG) to be consulted if disagreements persisted. </p> <p>Where the method of allocation concealment was not reported, or where additional information was required to appropriately assess study quality, we contacted the authors of these trials for clarification. We contacted the authors of three studies and received two replies; however, the responses did not uniformly clarify our questions. </p> </section> </section> <section id="CD003328-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <section id="CD003328-sec-0059"> <h5 class="title">Measures of treatment effect</h5> <p>We performed the analyses in Review Manager 5 (<a href="./references#CD003328-bbs2-0111" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). Where possible, we analysed data by intention‐to‐treat including all participants irrespective of compliance or follow‐up. </p> </section> <section id="CD003328-sec-0060"> <h5 class="title">Dichotomous outcomes</h5> <p>We expressed binary outcomes as odds ratios (OR) with 95% confidence intervals (CI). We estimated rare events (mortality and liver transplantation) by Peto ORs (<a href="./references#CD003328-bbs2-0048" title="BradburnMJ , DeeksJJ , BerlinJA , Russell LocalioA . Much ado about nothing: a comparison of the performance of meta‐analytical methods with rare events. Statistics in Medicine2007; Vol. 26, issue 1:53‐77. ">Bradburn 2007</a>). We used both a random‐effects model (<a href="./references#CD003328-bbs2-0064" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>) and a fixed‐effect model meta‐analysis to assess data analysed by OR (<a href="./references#CD003328-bbs2-0063" title="DeMetsDL . Practical aspects in monitoring: a brief review. Statistics in Medicine1987;6(7):753‐60. ">DeMets 1987</a>). We explored heterogeneity using the Chi<sup>2</sup> test with significance set at P value of 0.10 or less and we measured heterogeneity using the I<sup>2</sup> statistic (<a href="./references#CD003328-bbs2-0081" title="HigginsJPT , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21:1539‐58. ">Higgins 2002</a>). Where conclusions were different, we favoured a random‐effects model if there was a high degree of heterogeneity. </p> </section> <section id="CD003328-sec-0061"> <h5 class="title">Continuous outcomes</h5> <p>The main outcomes assessed in this systematic review were analysed as dichotomous outcomes as this is how ALT/AST and INR are consistently reported. Paracetamol pharmacokinetic data such as paracetamol concentration where possible was analysed as a continuous outcome. Data on participants were collected until discharge, death, or liver transplantation. We calculated the mean differences (MD; if trials used the same methods of measurement) and the standardised mean difference (SMD; if trials used different methods of measurement) with 95% CI for continuous outcomes. </p> </section> <section id="CD003328-sec-0062"> <h5 class="title">Mortality data</h5> <p>We analysed mortality data using hospital death (mortality) or liver transplantation as outcomes. We used estimates of log hazard ratios and standard errors. If the trialists did not report these data, we calculated the log hazard ratios and standard errors if possible (<a href="./references#CD003328-bbs2-0082" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org. ">Higgins 2011a</a>). We used the generic inverse‐variance method to meta‐analyse survival data (see Section 9.4.3.2 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003328-bbs2-0083" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. [Available from www.cochrane‐handbook.org.] ">Higgins 2011b</a>). </p> </section> </section> <section id="CD003328-sec-0063"> <h4 class="title">Dealing with missing data</h4> <section id="CD003328-sec-0064"> <h5 class="title">Dichotomous outcomes</h5> <p>If the trialists used the correct methodology (e.g. multiple imputation) to deal with missing data, we used these data in our primary analysis. </p> </section> <section id="CD003328-sec-0065"> <h5 class="title">Continuous outcomes</h5> <p>The only continuous outcomes intended to be analysed were the secondary outcomes of pharmacokinetic data such as paracetamol concentrations or area under the paracetamol curve. If trialists used correct methodology (e.g. multiple imputation) to deal with missing data, we intended to use these data in our primary analysis. If standard deviations (SD) were not reported, we intended to calculate the SDs using data from the trial if possible. Missing pharmacokinetic data were calculated by using non‐linear mixed effects modelling, provided all individual participant data were available. </p> </section> </section> <section id="CD003328-sec-0066"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the presence of statistical heterogeneity using the Chi<sup>2</sup> test with significance set at P &lt; 0.10 and measure the level of heterogeneity using the I<sup>2</sup> statistic (<a href="./references#CD003328-bbs2-0081" title="HigginsJPT , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21:1539‐58. ">Higgins 2002</a>; <a href="./references#CD003328-bbs2-0083" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. [Available from www.cochrane‐handbook.org.] ">Higgins 2011b</a>). </p> </section> <section id="CD003328-sec-0067"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to use a funnel plot to assess reporting bias had we included 10 or more trials per comparison. Using the asymmetry of the funnel plot, we planned to assess the risk of bias. For dichotomous outcomes, we planned to test asymmetry using the Harbord test (<a href="./references#CD003328-bbs2-0075" title="HarbordRM , EggerM , SterneJAC . A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints. Statistics in Medicine2006;25(20):3443‐57. ">Harbord 2006</a>). For continuous outcomes, we planned to use the regression asymmetry test (<a href="./references#CD003328-bbs2-0068" title="EggerM , DaveyGD , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple graphical test. BMJ (Clinical Research Ed.)1997;315:629‐34. ">Egger 1997</a>) and the adjusted rank correlation (<a href="./references#CD003328-bbs2-0046" title="BeggCB , MazumdarM . Operating characteristics of a rank correlation test for publication bias. Biometrics1994;50(4):1088‐101. [PUBMED: 7786990] ">Begg 1994</a>). </p> </section> <section id="CD003328-sec-0068"> <h4 class="title">Data synthesis</h4> <p>We planned to base our primary conclusions on the results of the primary outcomes with a low risk of bias at the end of intervention. We considered the results of primary outcomes with high risk of bias, and secondary outcomes, outcomes at maximum follow‐up, sensitivity analyses, and subgroup analyses as hypothesis‐generating tests (<a href="./references#CD003328-bbs2-0084" title="JakobsenJ , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. ">Jakobsen 2014</a>). </p> <section id="CD003328-sec-0069"> <h5 class="title">Meta‐analysis</h5> <p>We conducted the meta‐analyses according to the recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003328-bbs2-0082" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org. ">Higgins 2011a</a>). We used the statistical software Review Manager 5 (<a href="./references#CD003328-bbs2-0111" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) provided by Cochrane to analyse data (<a href="./references#CD003328-bbs2-0111" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD003328-sec-0070"> <h5 class="title">Assessment of significance</h5> <p>We planned to assess our intervention effects using both random‐effects model meta‐analyses (<a href="./references#CD003328-bbs2-0064" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>) and fixed‐effect model meta‐analyses (<a href="./references#CD003328-bbs2-0063" title="DeMetsDL . Practical aspects in monitoring: a brief review. Statistics in Medicine1987;6(7):753‐60. ">DeMets 1987</a>). We used the more conservative point estimate of the two (<a href="./references#CD003328-bbs2-0084" title="JakobsenJ , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. ">Jakobsen 2014</a>). The more conservative point estimate was the estimate closest to zero effect. If the two estimates were equal, we used the estimate with the widest CI. We used three primary outcomes and, therefore, we considered a P value of 0.025 or less as statistically significant (<a href="./references#CD003328-bbs2-0084" title="JakobsenJ , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. ">Jakobsen 2014</a>). We used the eight‐step procedure to assess if the thresholds for significance are crossed (<a href="./references#CD003328-bbs2-0084" title="JakobsenJ , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. ">Jakobsen 2014</a>). </p> </section> <section id="CD003328-sec-0071"> <h5 class="title">Trial Sequential Analysis</h5> <p>Traditional meta‐analysis runs the risk of random errors due to sparse data and repetitive testing of accumulating data when updating reviews. Therefore, we performed Trial Sequential Analysis (<a href="./references#CD003328-bbs2-0129" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA), 2011. ctu.dk/tsa/files/tsa_manual.pdf (accessed 20 May 2016). ">Thorlund 2011</a>; <a href="./references#CD003328-bbs2-0130" title="Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. Version 0.9 Beta. Copenhagen: Copenhagen Trial Unit, 2011. ">TSA 2011</a>; <a href="./references#CD003328-bbs2-0135" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta‐analysis. BMC Medical Research Methodology2017;17(1):39. ">Wetterslev 2017</a>) on the outcomes to calculate the required information size and assess the potential breach of the cumulative Z‐curve of the relevant trial sequential monitoring boundaries for benefit, harm, or futility to control for risks of type I errors and type II errors (<a href="./references#CD003328-bbs2-0049" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology2008;61(8):763‐9. [PUBMED: 18411040] ">Brok 2008</a>; <a href="./references#CD003328-bbs2-0133" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>; <a href="./references#CD003328-bbs2-0050" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive. Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [PUBMED: 18824466] ">Brok 2009</a>; <a href="./references#CD003328-bbs2-0127" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology2009;38(1):276‐86. [PUBMED: 18824467] ">Thorlund 2009</a>; <a href="./references#CD003328-bbs2-0134" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. [PUBMED: 20042080] ">Wetterslev 2009</a>; <a href="./references#CD003328-bbs2-0128" title="ThorlundK , AnemaA , MillsE . Interpreting meta‐analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV‐infected individuals. Clinical Epidemiology2010;2:57‐66. [PUBMED: 20865104] ">Thorlund 2010</a>). A more detailed description of Trial Sequential Analysis can be found at <a href="http://www.ctu.dk/tsa/" target="_blank">www.ctu.dk/tsa/</a> (<a href="./references#CD003328-bbs2-0129" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA), 2011. ctu.dk/tsa/files/tsa_manual.pdf (accessed 20 May 2016). ">Thorlund 2011</a>). </p> <p>For dichotomous outcomes, we planned to estimate the required information size based on the proportion of participants with an outcome in the control group, a relative risk reduction of 20%, an alpha of 2.5% (<a href="./references#CD003328-bbs2-0084" title="JakobsenJ , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. ">Jakobsen 2014</a>), a beta of 20%, and an assumed diversity of 20% as we had only one or two trials included in each Trial Sequential Analysis without any observable heterogeneity. For continuous outcomes, we planned to estimate the required information size based on the SD observed in the control group of trials with low risk of bias and a minimal relevant difference of 50% of this SD, an alpha of 2.5%, a beta of 20%, and the diversity suggested by the trials in the meta‐analysis. </p> </section> </section> <section id="CD003328-sec-0072"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We intended to conduct the following subgroup analyses.</p> <p> <ul id="CD003328-list-0012"> <li> <p>Outcomes at a low risk of bias compared to outcomes at a high risk of bias.</p> </li> <li> <p>Age of participants categorised into 10‐year groups.</p> </li> <li> <p>Risk of hepatotoxicity at baseline (according to paracetamol concentration data).</p> </li> </ul> </p> <p>However, due to insufficient data, these analyses could not be conducted.</p> </section> <section id="CD003328-sec-0073"> <h4 class="title">Sensitivity analysis</h4> <p>To assess the potential impact of missing data for dichotomous outcomes, we intended to perform the following two sensitivity analyses. </p> <p> <ul id="CD003328-list-0013"> <li> <p>'Best‐worst case' scenario: we assumed that all participants lost to follow‐up in the intervention group survived, had no serious adverse event, and had no morbidity; and all those participants with missing outcomes in the control group did not survive, had a serious adverse event, and had morbidity. </p> </li> <li> <p>'Worst‐best case' scenario: we assumed that all participants lost to follow‐up in the intervention group survived, had a serious adverse event, and had morbidity; and that all those participants lost to follow‐up in the control group had survived, had no serious adverse event, and had no morbidity. </p> </li> </ul> </p> <p>To assess the potential impact of missing SDs for continuous outcomes, we intended to perform the following sensitivity analysis. </p> <p> <ul id="CD003328-list-0014"> <li> <p>Where SDs were missing and it was not possible to calculate them, we planned to impute SDs from trials with similar populations and low risk of bias. If we found no such trials, we intended to impute SDs from trials with a similar population. As the final option, we planned to impute SDs from all trials. </p> </li> </ul> </p> <section id="CD003328-sec-0074"> <h5 class="title">'Summary of findings' tables</h5> <p>We used GRADE to assess the quality of the evidence (<a href="./references#CD003328-bbs2-0074" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed.)2008;336:924‐6. ">Guyatt 2008</a>) associated with each of the major outcomes in our review constructing 'Summary of findings' tables using GRADE software (<a href="http://ims.cochrane.org/revman/other-resources/gradepro" target="_blank">ims.cochrane.org/revman/other‐resources/gradepro</a>). The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The quality measure of a body of evidence considers the within‐study risk of bias, indirectness of the evidence, heterogeneity of data, imprecision of effect estimates, and risk of publication bias. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003328-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003328-sec-0075"></div> <section id="CD003328-sec-0076"> <h3 class="title">Description of studies</h3> <section id="CD003328-sec-0077"> <h4 class="title">Results of the search</h4> <p>See flow chart (<a href="#CD003328-fig-0001">Figure 1</a>). An updated search was performed in October 2013 that identified 220 references. We excluded 63 as they were animal studies or studies that did not involve paracetamol ingestion. A further 61 were non‐randomised clinical studies, 31 were healthy volunteer studies and 25 were duplicate references. We reviewed 40 full‐text articles. Of these, we included 10 clinical trials and one quasi‐randomised clinical trial. One abandoned randomised clinical trial was identified in the clinical trials database. The search was updated in June 2015 and identified 44 new references of which two were randomised clinical trials, one was previously identified and one was reviewed and excluded as it was a randomised clinical trial of albumin dialysis with the Molecular Adsorbent Recirculating System (MARS) used for the treatment of fulminant liver failure. The search was updated again in January 2017, identifying 49 new references, four of which were randomised clinical trials that had been identified previously. See: <a href="./references#CD003328-sec-0135" title="">Characteristics of included studies</a>; <a href="./references#CD003328-sec-0136" title="">Characteristics of excluded studies</a> tables. Below, we describe the trials according to the assessed interventions. </p> <div class="figure" id="CD003328-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow chart: search strategy and results." data-id="CD003328-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow chart: search strategy and results.</p> </div> </div> </div> </section> <section id="CD003328-sec-0078"> <h4 class="title">Included studies</h4> <section id="CD003328-sec-0079"> <h5 class="title">Prevention of absorption</h5> <p>One trial allocated participants to activated charcoal, ipecacuanha, gastric lavage, or no intervention (<a href="./references#CD003328-bbs2-0011" title="UnderhillTJ , GreeneMK , DoveAF . A comparison of the efficacy of gastric lavage, ipecacuanha and activated charcoal in the emergency management of paracetamol overdose. Archives of Emergency Medicine1990;7:148‐54. ">Underhill 1990</a>). The primary outcome was the mean percentage fall in paracetamol concentration (from the first to the last sample (150 minutes). </p> </section> <section id="CD003328-sec-0080"> <h5 class="title">Antidotes</h5> <p>Three trials randomised participants to different antidotes (methionine, cysteine, cysteamine, or dimercaprol) (<a href="./references#CD003328-bbs2-0003" title="DouglasAP , HamlynAN , JamesO . Controlled trial of cysteamine in treatment of acute paracetamol poisoning. Lancet1976;2:111‐5. ">Douglas 1976a</a>; <a href="./references#CD003328-bbs2-0007" title="HughesRD , GazzardBG , HanidMA , TrewbyPN , Murray‐LyonIM , DavisM , et al. Controlled trial of cysteamine and dimercaprol after paracetamol overdose. BMJ (Clinical Research Ed.)1977;2:1395. ">Hughes 1977</a>; <a href="./references#CD003328-bbs2-0006" title="HamlynAN , LesnaM , RecordCO , SmithPA , PathFRC , WatsonAJ . Methionine and cysteamine in paracetamol overdose, prospective controlled trial of early therapy. Journal of International Medical Research1981;9:226‐31. ">Hamlyn 1981</a>). One trial randomised participants with paracetamol‐induced fulminant hepatic failure to acetylcysteine versus placebo (<a href="./references#CD003328-bbs2-0008" title="KeaysR , HarrisonPM , WendonJA , ForbesA , GoveC , AlexanderGJM , et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure. BMJ (Clinical Research Ed.)1991;303:1026‐9. ">Keays 1991</a>). </p> <p>Some randomised clinical trials looked at differing acetylcysteine regimens to decrease the rate of adverse effects from acetylcysteine treatment (<a href="./references#CD003328-bbs2-0009" title="KerrF , DawsonA , WhyteIM , BuckleyN , MurrayL , GraudinsA , et al. The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N‐acetylcysteine. Annals of Emergency Medicine2005;45(4):402‐8. [MEDLINE: PMID: 15795719] ">Kerr 2005</a>; <a href="./references#CD003328-bbs2-0002" title="BatemanDN , DearJW , ThanacoodyHK , ThomasSH , EddlestonM , SandilandsEA , et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet2014;383(9918):607‐704. [DOI: 10.1016/S0140‐6736(13)62062‐0] ">Bateman 2014</a>). One trial randomised participants to receive either intravenous or oral acetylcysteine (<a href="./references#CD003328-bbs2-0001" title="ArefiM , BehnoushB , PourazizH , YousefinejadV . Comparison of oral and intravenous N‐acetylcysteine administration in the treatment of acetaminophen poisoning. Scientific Journal of Kurdistan University of Medical Sciences2013;18(2):36‐43. [] ">Arefi 2013</a>). Another trial randomised participants to intravenous or intravenous plus oral acetylcysteine. This trial excluded post hoc 40% of participants who vomited twice after oral acetylcysteine was given, and it was unclear what the treatment and outcomes were for these randomised participants (<a href="./references#CD003328-bbs2-0004" title="Eizadi‐MoodN , SabzghabaeeAM , SiadatS , YaraghiA , ShariatiM , GheshlaghiF , et al. Intravenous acetylcysteine versus oral and Intravenous acetylcysteine: does a combination therapy decrease side effects of acetylcysteine?. Pakistan Journal of Medical Sciences2013;29(1 Suppl):308‐11. [] ">Eizadi‐Mood 2013</a>). Two trials randomised participants to different infusion rates of intravenous acetylcysteine compared with the traditional 20.25‐hour intravenous regimen (<a href="./references#CD003328-bbs2-0009" title="KerrF , DawsonA , WhyteIM , BuckleyN , MurrayL , GraudinsA , et al. The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N‐acetylcysteine. Annals of Emergency Medicine2005;45(4):402‐8. [MEDLINE: PMID: 15795719] ">Kerr 2005</a>; <a href="./references#CD003328-bbs2-0002" title="BatemanDN , DearJW , ThanacoodyHK , ThomasSH , EddlestonM , SandilandsEA , et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet2014;383(9918):607‐704. [DOI: 10.1016/S0140‐6736(13)62062‐0] ">Bateman 2014</a>). </p> <p>One multicentre randomised, blind clinical trial, started in 2010, was registered in the US by Cumberland Pharmaceuticals, and compared an intravenous acetylcysteine regimen with a two‐bag regimen (200 mg/kg over four hours followed by 100 mg/kg over 16 hours) versus the traditional acetylcysteine regimen (<a href="./references#CD003328-bbs2-0010" title="CumberlandPharmaceuticals . A multi‐center, double‐blind, randomized, controlled study to determine the efficacy and safety of a new formulation of acetylcysteine injection. clinicaltrials.gov/ct2/show/study/NCT01118663 Date first received: 4 August 2014. ">NCT01118663</a>). This trial was terminated early after enrolling only 17 participants, although the number to be recruited was not reported (<a href="./references#CD003328-bbs2-0010" title="CumberlandPharmaceuticals . A multi‐center, double‐blind, randomized, controlled study to determine the efficacy and safety of a new formulation of acetylcysteine injection. clinicaltrials.gov/ct2/show/study/NCT01118663 Date first received: 4 August 2014. ">NCT01118663</a>). </p> <p>There was one quasi‐randomised trial that studied cimetidine plus acetylcysteine (<a href="./references#CD003328-bbs2-0015" title="BurkhartKK , JancoN , KuligKW , RumackBH . Cimetidine as adjunctive treatment for acetaminophen overdose. Human &amp; Experimental Toxicology1995;14(3):299‐304. ">Burkhart 1995</a>). </p> </section> <section id="CD003328-sec-0081"> <h5 class="title">Extracorporeal treatments</h5> <p>One trial randomised participants with acute paracetamol overdose to charcoal haemoperfusion versus no intervention (<a href="./references#CD003328-bbs2-0005" title="GazzardBG , WillsonRA , WestonMJ , ThompsonRPH , WilliamsR . Charcoal haemoperfusion for paracetamol overdose. British Journal of Clinical Pharmacology1974;1:271‐5. ">Gazzard 1974a</a>). </p> </section> <section id="CD003328-sec-0082"> <h5 class="title">Other interventions</h5> <p>One trial looked at ondansetron to decrease the risk of vomiting as an adjunct to acetylcysteine treatment (<a href="./references#CD003328-bbs2-0002" title="BatemanDN , DearJW , ThanacoodyHK , ThomasSH , EddlestonM , SandilandsEA , et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet2014;383(9918):607‐704. [DOI: 10.1016/S0140‐6736(13)62062‐0] ">Bateman 2014</a>). This was a part of the trial that assessed a modified 12‐hour acetylcysteine regimen. </p> </section> </section> <section id="CD003328-sec-0083"> <h4 class="title">Excluded studies</h4> <p>We excluded 33 for reasons given in the <a href="./references#CD003328-sec-0136" title="">Characteristics of excluded studies</a> table. </p> <section id="CD003328-sec-0084"> <h5 class="title">Studies awaiting classification</h5> <p>We found no studies awaiting classification.</p> </section> <section id="CD003328-sec-0085"> <h5 class="title">Ongoing studies</h5> <p>We found no ongoing studies.</p> </section> </section> </section> <section id="CD003328-sec-0086"> <h3 class="title">Risk of bias in included studies</h3> <p><b>Allocation (selection bias)</b> </p> <p>Generation of the allocation sequence was often not specified, and only five trials described details of randomisation (<a href="./references#CD003328-bbs2-0003" title="DouglasAP , HamlynAN , JamesO . Controlled trial of cysteamine in treatment of acute paracetamol poisoning. Lancet1976;2:111‐5. ">Douglas 1976a</a>; <a href="./references#CD003328-bbs2-0006" title="HamlynAN , LesnaM , RecordCO , SmithPA , PathFRC , WatsonAJ . Methionine and cysteamine in paracetamol overdose, prospective controlled trial of early therapy. Journal of International Medical Research1981;9:226‐31. ">Hamlyn 1981</a>; <a href="./references#CD003328-bbs2-0009" title="KerrF , DawsonA , WhyteIM , BuckleyN , MurrayL , GraudinsA , et al. The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N‐acetylcysteine. Annals of Emergency Medicine2005;45(4):402‐8. [MEDLINE: PMID: 15795719] ">Kerr 2005</a>; <a href="./references#CD003328-bbs2-0004" title="Eizadi‐MoodN , SabzghabaeeAM , SiadatS , YaraghiA , ShariatiM , GheshlaghiF , et al. Intravenous acetylcysteine versus oral and Intravenous acetylcysteine: does a combination therapy decrease side effects of acetylcysteine?. Pakistan Journal of Medical Sciences2013;29(1 Suppl):308‐11. [] ">Eizadi‐Mood 2013</a>; <a href="./references#CD003328-bbs2-0002" title="BatemanDN , DearJW , ThanacoodyHK , ThomasSH , EddlestonM , SandilandsEA , et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet2014;383(9918):607‐704. [DOI: 10.1016/S0140‐6736(13)62062‐0] ">Bateman 2014</a>). Allocation concealment was similarly not described in detail, with most trials at unclear risk of bias, except for two randomised trials (<a href="./references#CD003328-bbs2-0008" title="KeaysR , HarrisonPM , WendonJA , ForbesA , GoveC , AlexanderGJM , et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure. BMJ (Clinical Research Ed.)1991;303:1026‐9. ">Keays 1991</a>; <a href="./references#CD003328-bbs2-0002" title="BatemanDN , DearJW , ThanacoodyHK , ThomasSH , EddlestonM , SandilandsEA , et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet2014;383(9918):607‐704. [DOI: 10.1016/S0140‐6736(13)62062‐0] ">Bateman 2014</a>). </p> <p><b>Blinding (performance bias and detection bias)</b> </p> <p>All randomised trials were conducted unblinded except one, which used placebo but failed to mask the aroma (<a href="./references#CD003328-bbs2-0008" title="KeaysR , HarrisonPM , WendonJA , ForbesA , GoveC , AlexanderGJM , et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure. BMJ (Clinical Research Ed.)1991;303:1026‐9. ">Keays 1991</a>). Accordingly, we judged most trials to be at high risk of bias due to lack of blinding. In one trial, the control group was given supportive treatment in a different hospital, which may have seriously affected the value of this comparison group and questions how the randomisation was carried out (<a href="./references#CD003328-bbs2-0011" title="UnderhillTJ , GreeneMK , DoveAF . A comparison of the efficacy of gastric lavage, ipecacuanha and activated charcoal in the emergency management of paracetamol overdose. Archives of Emergency Medicine1990;7:148‐54. ">Underhill 1990</a>). One trial of intravenous versus a combination of oral plus intravenous acetylcysteine had nausea and vomiting from acetylcysteine treatment as a primary outcome. However, participants were excluded and not analysed if they vomited twice after oral acetylcysteine, which resulted in exclusion of 40% of the participants from the analysis and biased the results (<a href="./references#CD003328-bbs2-0004" title="Eizadi‐MoodN , SabzghabaeeAM , SiadatS , YaraghiA , ShariatiM , GheshlaghiF , et al. Intravenous acetylcysteine versus oral and Intravenous acetylcysteine: does a combination therapy decrease side effects of acetylcysteine?. Pakistan Journal of Medical Sciences2013;29(1 Suppl):308‐11. [] ">Eizadi‐Mood 2013</a>). </p> <p><b>Incomplete outcome data (attrition bias)</b> </p> <p>The trials varied in their reporting of missing or incomplete data; four trials were judged to be at low risk of bias (<a href="./references#CD003328-bbs2-0005" title="GazzardBG , WillsonRA , WestonMJ , ThompsonRPH , WilliamsR . Charcoal haemoperfusion for paracetamol overdose. British Journal of Clinical Pharmacology1974;1:271‐5. ">Gazzard 1974a</a>; <a href="./references#CD003328-bbs2-0003" title="DouglasAP , HamlynAN , JamesO . Controlled trial of cysteamine in treatment of acute paracetamol poisoning. Lancet1976;2:111‐5. ">Douglas 1976a</a>; <a href="./references#CD003328-bbs2-0007" title="HughesRD , GazzardBG , HanidMA , TrewbyPN , Murray‐LyonIM , DavisM , et al. Controlled trial of cysteamine and dimercaprol after paracetamol overdose. BMJ (Clinical Research Ed.)1977;2:1395. ">Hughes 1977</a>; <a href="./references#CD003328-bbs2-0002" title="BatemanDN , DearJW , ThanacoodyHK , ThomasSH , EddlestonM , SandilandsEA , et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet2014;383(9918):607‐704. [DOI: 10.1016/S0140‐6736(13)62062‐0] ">Bateman 2014</a>). Four trials did not mention if they had missing outcome data or how missing data were handled, so we judged them to be at unclear risk of attrition bias (<a href="./references#CD003328-bbs2-0006" title="HamlynAN , LesnaM , RecordCO , SmithPA , PathFRC , WatsonAJ . Methionine and cysteamine in paracetamol overdose, prospective controlled trial of early therapy. Journal of International Medical Research1981;9:226‐31. ">Hamlyn 1981</a>; <a href="./references#CD003328-bbs2-0011" title="UnderhillTJ , GreeneMK , DoveAF . A comparison of the efficacy of gastric lavage, ipecacuanha and activated charcoal in the emergency management of paracetamol overdose. Archives of Emergency Medicine1990;7:148‐54. ">Underhill 1990</a>; <a href="./references#CD003328-bbs2-0008" title="KeaysR , HarrisonPM , WendonJA , ForbesA , GoveC , AlexanderGJM , et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure. BMJ (Clinical Research Ed.)1991;303:1026‐9. ">Keays 1991</a>; <a href="./references#CD003328-bbs2-0001" title="ArefiM , BehnoushB , PourazizH , YousefinejadV . Comparison of oral and intravenous N‐acetylcysteine administration in the treatment of acetaminophen poisoning. Scientific Journal of Kurdistan University of Medical Sciences2013;18(2):36‐43. [] ">Arefi 2013</a>). We judged two trials to be at high risk of attrition bias because both of them excluded a large number of participants from the analysis (<a href="./references#CD003328-bbs2-0009" title="KerrF , DawsonA , WhyteIM , BuckleyN , MurrayL , GraudinsA , et al. The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N‐acetylcysteine. Annals of Emergency Medicine2005;45(4):402‐8. [MEDLINE: PMID: 15795719] ">Kerr 2005</a>; <a href="./references#CD003328-bbs2-0004" title="Eizadi‐MoodN , SabzghabaeeAM , SiadatS , YaraghiA , ShariatiM , GheshlaghiF , et al. Intravenous acetylcysteine versus oral and Intravenous acetylcysteine: does a combination therapy decrease side effects of acetylcysteine?. Pakistan Journal of Medical Sciences2013;29(1 Suppl):308‐11. [] ">Eizadi‐Mood 2013</a>). </p> <p><b>Selective reporting (reporting bias)</b> </p> <p>We judged six trials to be at low risk of reporting bias (<a href="./references#CD003328-bbs2-0005" title="GazzardBG , WillsonRA , WestonMJ , ThompsonRPH , WilliamsR . Charcoal haemoperfusion for paracetamol overdose. British Journal of Clinical Pharmacology1974;1:271‐5. ">Gazzard 1974a</a>; <a href="./references#CD003328-bbs2-0003" title="DouglasAP , HamlynAN , JamesO . Controlled trial of cysteamine in treatment of acute paracetamol poisoning. Lancet1976;2:111‐5. ">Douglas 1976a</a>; <a href="./references#CD003328-bbs2-0007" title="HughesRD , GazzardBG , HanidMA , TrewbyPN , Murray‐LyonIM , DavisM , et al. Controlled trial of cysteamine and dimercaprol after paracetamol overdose. BMJ (Clinical Research Ed.)1977;2:1395. ">Hughes 1977</a>; <a href="./references#CD003328-bbs2-0006" title="HamlynAN , LesnaM , RecordCO , SmithPA , PathFRC , WatsonAJ . Methionine and cysteamine in paracetamol overdose, prospective controlled trial of early therapy. Journal of International Medical Research1981;9:226‐31. ">Hamlyn 1981</a>; <a href="./references#CD003328-bbs2-0008" title="KeaysR , HarrisonPM , WendonJA , ForbesA , GoveC , AlexanderGJM , et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure. BMJ (Clinical Research Ed.)1991;303:1026‐9. ">Keays 1991</a>; <a href="./references#CD003328-bbs2-0002" title="BatemanDN , DearJW , ThanacoodyHK , ThomasSH , EddlestonM , SandilandsEA , et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet2014;383(9918):607‐704. [DOI: 10.1016/S0140‐6736(13)62062‐0] ">Bateman 2014</a>). We judged one trial to be at high risk of reporting bias because the trial authors did not report on their planned outcomes (<a href="./references#CD003328-bbs2-0004" title="Eizadi‐MoodN , SabzghabaeeAM , SiadatS , YaraghiA , ShariatiM , GheshlaghiF , et al. Intravenous acetylcysteine versus oral and Intravenous acetylcysteine: does a combination therapy decrease side effects of acetylcysteine?. Pakistan Journal of Medical Sciences2013;29(1 Suppl):308‐11. [] ">Eizadi‐Mood 2013</a>). In three trials, the risk of reporting bias was unclear (<a href="./references#CD003328-bbs2-0011" title="UnderhillTJ , GreeneMK , DoveAF . A comparison of the efficacy of gastric lavage, ipecacuanha and activated charcoal in the emergency management of paracetamol overdose. Archives of Emergency Medicine1990;7:148‐54. ">Underhill 1990</a>; <a href="./references#CD003328-bbs2-0009" title="KerrF , DawsonA , WhyteIM , BuckleyN , MurrayL , GraudinsA , et al. The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N‐acetylcysteine. Annals of Emergency Medicine2005;45(4):402‐8. [MEDLINE: PMID: 15795719] ">Kerr 2005</a>; <a href="./references#CD003328-bbs2-0001" title="ArefiM , BehnoushB , PourazizH , YousefinejadV . Comparison of oral and intravenous N‐acetylcysteine administration in the treatment of acetaminophen poisoning. Scientific Journal of Kurdistan University of Medical Sciences2013;18(2):36‐43. [] ">Arefi 2013</a>). <a href="./references#CD003328-bbs2-0001" title="ArefiM , BehnoushB , PourazizH , YousefinejadV . Comparison of oral and intravenous N‐acetylcysteine administration in the treatment of acetaminophen poisoning. Scientific Journal of Kurdistan University of Medical Sciences2013;18(2):36‐43. [] ">Arefi 2013</a> was not a registered trial and the primary outcome was unclear. <a href="./references#CD003328-bbs2-0011" title="UnderhillTJ , GreeneMK , DoveAF . A comparison of the efficacy of gastric lavage, ipecacuanha and activated charcoal in the emergency management of paracetamol overdose. Archives of Emergency Medicine1990;7:148‐54. ">Underhill 1990</a> did not report on the relevant clinical outcomes such as need for treatment with antidote, and <a href="./references#CD003328-bbs2-0009" title="KerrF , DawsonA , WhyteIM , BuckleyN , MurrayL , GraudinsA , et al. The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N‐acetylcysteine. Annals of Emergency Medicine2005;45(4):402‐8. [MEDLINE: PMID: 15795719] ">Kerr 2005</a> had two investigators to make a judgement on the attribution of an event, and it is unclear whether bias might have been introduced in the process of adjudicating on events. </p> <p><b>Other potential sources of bias</b> </p> <p>We judged all but two trials at unclear risk of bias for potential other sources of bias because these trials did not have a sample size calculation, did not perform intention to treat analysis, or did not report on the number of participants screened for randomisation or number of participants excluded from the trial or analysis. <a href="./references#CD003328-bbs2-0004" title="Eizadi‐MoodN , SabzghabaeeAM , SiadatS , YaraghiA , ShariatiM , GheshlaghiF , et al. Intravenous acetylcysteine versus oral and Intravenous acetylcysteine: does a combination therapy decrease side effects of acetylcysteine?. Pakistan Journal of Medical Sciences2013;29(1 Suppl):308‐11. [] ">Eizadi‐Mood 2013</a> was at high risk of bias because of the lack of detail regarding the high number of participants excluded from the trial. Thus, only one trial was judged to be at low risk of bias for this domain (<a href="./references#CD003328-bbs2-0002" title="BatemanDN , DearJW , ThanacoodyHK , ThomasSH , EddlestonM , SandilandsEA , et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet2014;383(9918):607‐704. [DOI: 10.1016/S0140‐6736(13)62062‐0] ">Bateman 2014</a>). </p> <p>In conclusion, the trials varied considerably for each risk of bias domain. <a href="#CD003328-fig-0002">Figure 2</a> shows the percentages across all included trials of each risk of bias item as judged by the review authors. <a href="#CD003328-fig-0003">Figure 3</a> shows the risk of bias in each study as judged by the review authors. </p> <div class="figure" id="CD003328-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003328-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003328-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003328-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> <section id="CD003328-sec-0087"> <h3 class="title" id="CD003328-sec-0087">Effects of interventions</h3> <p>See: <a href="./full#CD003328-tbl-0001"><b>Summary of findings for the main comparison</b> Methionine and supportive treatment compared with supportive treatment for paracetamol (acetaminophen) overdose</a>; <a href="./full#CD003328-tbl-0002"><b>Summary of findings 2</b> Cysteamine compared with no intervention for paracetamol (acetaminophen) overdose</a>; <a href="./full#CD003328-tbl-0003"><b>Summary of findings 3</b> Cysteamine compared with dimercaprol for paracetamol (acetaminophen) overdose</a>; <a href="./full#CD003328-tbl-0004"><b>Summary of findings 4</b> Cysteamine compared with methionine (randomised trials) for paracetamol (acetaminophen) overdose</a>; <a href="./full#CD003328-tbl-0005"><b>Summary of findings 5</b> Standard intravenous acetylcysteine regimen (20.5 hour) compared with shorter intravenous acetylcysteine regimen (12 hour) for paracetamol (acetaminophen) overdose</a>; <a href="./full#CD003328-tbl-0006"><b>Summary of findings 6</b> Oral compared with intravenous acetylcysteine for paracetamol (acetaminophen) overdose</a>; <a href="./full#CD003328-tbl-0007"><b>Summary of findings 7</b> Intravenous acetylcysteine compared with placebo in people with fulminant hepatic failure for paracetamol (acetaminophen) overdose</a>; <a href="./full#CD003328-tbl-0008"><b>Summary of findings 8</b> Initial infusion rate of intravenous acetylcysteine over 15 minutes compared with 60 minutes for paracetamol (acetaminophen) overdose</a>; <a href="./full#CD003328-tbl-0009"><b>Summary of findings 9</b> Oral plus intravenous acetylcysteine compared with intravenous acetylcysteine for paracetamol (acetaminophen) overdose</a>; <a href="./full#CD003328-tbl-0010"><b>Summary of findings 10</b> Charcoal haemoperfusion compared with no intervention for paracetamol (acetaminophen) overdose</a> </p> <p>The 11 included randomised clinical trials differed substantially in inclusion criteria, interventions, and outcome measures. Therefore, it was only possible to perform one meta‐analysis that addressed two of our outcomes. For an overview, we presented single trials in the meta‐analyses and Trial Sequential Analysis. Planned subgroup analyses was not performed due to the small number of trials and inadequate data to perform such analyses. </p> <section id="CD003328-sec-0088"> <h4 class="title">Activated charcoal, gastric lavage and ipecacuanha</h4> <section id="CD003328-sec-0089"> <h5 class="title">Plasma paracetamol concentration</h5> <p>One small trial (60 participants) found that the mean percentage fall in plasma paracetamol concentration was significantly greater with activated charcoal (52.3%, SD 13.6%) compared with gastric lavage (39.3%, SD 14.7%) or ipecacuanha (40.7%, SD 18.3%) if given within four hours after ingestion (P = 0.03) (<a href="./references#CD003328-bbs2-0011" title="UnderhillTJ , GreeneMK , DoveAF . A comparison of the efficacy of gastric lavage, ipecacuanha and activated charcoal in the emergency management of paracetamol overdose. Archives of Emergency Medicine1990;7:148‐54. ">Underhill 1990</a>). There was no significant difference between gastric lavage and ipecacuanha (P = 0.081), although both were more effective than no treatment at limiting the absorption of paracetamol. However, the time interval between ingestion and intervention in the different groups was not clearly reported. There were potential areas of bias with the control group. First, the control group was given supportive treatment in a different hospital, which questions how randomisation was carried out. Furthermore, supportive treatment was stopped early due to "ethical reasons," there was an increase in paracetamol levels in four out of five participants in this group between the first and the last sample compared to paracetamol levels falling in the intervention groups. Therefore, the value of this trial was limited. </p> </section> </section> <section id="CD003328-sec-0090"> <h4 class="title">Antidotes</h4> <section id="CD003328-sec-0091"> <h5 class="title">Methionine versus no intervention</h5> <section id="CD003328-sec-0092"> <h6 class="title">Mortality</h6> <p>Based on one trial, there was no beneficial effect of methionine compared with no intervention on mortality (OR not reported by authors, OR for mortality calculated using Fisher's exact test, OR 0.31, 95% CI 0.01 to 8.31; P = 1.00) (for comparison, see <a href="./references#CD003328-fig-0007" title="">Analysis 1.1</a>: Peto OR 0.14, 95% CI 0.00 to 6.82, that is less valid as we only have one trial) (<a href="./references#CD003328-bbs2-0006" title="HamlynAN , LesnaM , RecordCO , SmithPA , PathFRC , WatsonAJ . Methionine and cysteamine in paracetamol overdose, prospective controlled trial of early therapy. Journal of International Medical Research1981;9:226‐31. ">Hamlyn 1981</a>). </p> </section> <section id="CD003328-sec-0093"> <h6 class="title">Hepatotoxicity</h6> <p>Compared with no intervention, methionine reduced the number of people with hepatotoxicity (OR not reported by authors, OR for hepatotoxicity calculated using Fisher's exact test; OR 0.05, 95% CI 0.004 to 0.51; P = 0.01; <a href="./references#CD003328-fig-0008" title="">Analysis 1.2</a>: OR 0.05, 95% CI 0.01 to 0.53). Trial Sequential Analysis (not shown) demonstrated that the diversity‐adjusted required information size (DARIS) was 9731 participants of which they only accrued 26 participants corresponding to 0.26% of DARIS. This DARIS was calculated based on a proportion of deaths of 10% in the control group, a relative risk reduction of 20%, an alpha of 2.5%, a beta of 20% (corresponding to a power of 80%), and an assumed diversity of 20%. The Trial Sequential Analysis‐adjusted CI could not be estimated due to the paucity of data. See <a href="./full#CD003328-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> </section> <section id="CD003328-sec-0094"> <h5 class="title">Cysteamine versus no intervention or methionine or dimercaprol</h5> <section id="CD003328-sec-0095"> <h6 class="title">Mortality</h6> <p>Compared with no intervention, cysteamine had no effect on mortality (<a href="./references#CD003328-fig-0009" title="">Analysis 2.1</a>: Peto OR 0.53, 95% CI 0.05 to 5.22, 2 trials, 65 participants) (<a href="./references#CD003328-bbs2-0003" title="DouglasAP , HamlynAN , JamesO . Controlled trial of cysteamine in treatment of acute paracetamol poisoning. Lancet1976;2:111‐5. ">Douglas 1976a</a>; <a href="./references#CD003328-bbs2-0006" title="HamlynAN , LesnaM , RecordCO , SmithPA , PathFRC , WatsonAJ . Methionine and cysteamine in paracetamol overdose, prospective controlled trial of early therapy. Journal of International Medical Research1981;9:226‐31. ">Hamlyn 1981</a>). </p> <p>The <a href="./references#CD003328-bbs2-0006" title="HamlynAN , LesnaM , RecordCO , SmithPA , PathFRC , WatsonAJ . Methionine and cysteamine in paracetamol overdose, prospective controlled trial of early therapy. Journal of International Medical Research1981;9:226‐31. ">Hamlyn 1981</a> trial compared cysteamine to methionine (27 participants). There were no deaths in either group (<a href="./references#CD003328-fig-0011" title="">Analysis 3.1</a>: Peto OR: not estimable). </p> <p>One trial (52 participants) found no difference between cysteamine and dimercaprol on mortality (OR not reported, OR for mortality calculated using Fisher's exact test, OR 0.32, 95% CI 0.01 to 8.25; P = 1.00) (<a href="./references#CD003328-fig-0013" title="">Analysis 4.1</a>: Peto OR 0.14, 95% CI 0.00 to 6.82) (<a href="./references#CD003328-bbs2-0007" title="HughesRD , GazzardBG , HanidMA , TrewbyPN , Murray‐LyonIM , DavisM , et al. Controlled trial of cysteamine and dimercaprol after paracetamol overdose. BMJ (Clinical Research Ed.)1977;2:1395. ">Hughes 1977</a>). One participant who received dimercaprol died. See <a href="./full#CD003328-tbl-0003">summary of findings Table 3</a>. </p> </section> <section id="CD003328-sec-0096"> <h6 class="title">Hepatotoxicity</h6> <p>Compared with no intervention, cysteamine seemed to decrease the risk of developing hepatotoxicity (<a href="./references#CD003328-fig-0010" title="">Analysis 2.2</a>: OR 0.09, 95% CI 0.02 to 0.35, 2 trials, 65 participants) (<a href="./references#CD003328-bbs2-0003" title="DouglasAP , HamlynAN , JamesO . Controlled trial of cysteamine in treatment of acute paracetamol poisoning. Lancet1976;2:111‐5. ">Douglas 1976a</a>; <a href="./references#CD003328-bbs2-0006" title="HamlynAN , LesnaM , RecordCO , SmithPA , PathFRC , WatsonAJ . Methionine and cysteamine in paracetamol overdose, prospective controlled trial of early therapy. Journal of International Medical Research1981;9:226‐31. ">Hamlyn 1981</a>). Douglas and colleagues had a control group with higher paracetamol concentration before treatment (<a href="./references#CD003328-bbs2-0003" title="DouglasAP , HamlynAN , JamesO . Controlled trial of cysteamine in treatment of acute paracetamol poisoning. Lancet1976;2:111‐5. ">Douglas 1976a</a>), which may have introduced bias into the comparison group. The <a href="./references#CD003328-bbs2-0006" title="HamlynAN , LesnaM , RecordCO , SmithPA , PathFRC , WatsonAJ . Methionine and cysteamine in paracetamol overdose, prospective controlled trial of early therapy. Journal of International Medical Research1981;9:226‐31. ">Hamlyn 1981</a> trial was essentially a continuation of the <a href="./references#CD003328-bbs2-0003" title="DouglasAP , HamlynAN , JamesO . Controlled trial of cysteamine in treatment of acute paracetamol poisoning. Lancet1976;2:111‐5. ">Douglas 1976a</a> trial, and results of four of the participants were used in both trials (<a href="./references#CD003328-bbs2-0003" title="DouglasAP , HamlynAN , JamesO . Controlled trial of cysteamine in treatment of acute paracetamol poisoning. Lancet1976;2:111‐5. ">Douglas 1976a</a>; <a href="./references#CD003328-bbs2-0006" title="HamlynAN , LesnaM , RecordCO , SmithPA , PathFRC , WatsonAJ . Methionine and cysteamine in paracetamol overdose, prospective controlled trial of early therapy. Journal of International Medical Research1981;9:226‐31. ">Hamlyn 1981</a>). As it could not be determined which these participants were, the same participant data were analysed twice for these four people. Trial Sequential Analysis of cysteamine versus control on hepatotoxicity demonstrated that this effect was not statistically significant and the Trial Sequential Analysis‐adjusted CI ranged from 0.00 to 24.0 (<a href="#CD003328-fig-0004">Figure 4</a>). See <a href="./full#CD003328-tbl-0002">summary of findings Table 2</a>. </p> <div class="figure" id="CD003328-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of cysteamine versus control on hepatotoxicity defined as aspartate aminotransferase (AST) above 1000 IU/L. The diversity‐adjusted required information size (DARIS) was 982 participants based on a proportion of 53% with the outcome in the control group (Pc); a risk reduction of 20%; an alpha (a) of 2.5%; a beta (b) of 20% (equivalent to a power of 80%); and an assumed diversity of 20%. As demonstrated the trial sequential monitoring boundaries for benefit, harm, or futility were crossed by the cumulative Z value." data-id="CD003328-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis of cysteamine versus control on hepatotoxicity defined as aspartate aminotransferase (AST) above 1000 IU/L. The diversity‐adjusted required information size (DARIS) was 982 participants based on a proportion of 53% with the outcome in the control group (Pc); a risk reduction of 20%; an alpha (a) of 2.5%; a beta (b) of 20% (equivalent to a power of 80%); and an assumed diversity of 20%. As demonstrated the trial sequential monitoring boundaries for benefit, harm, or futility were crossed by the cumulative Z value. </p> </div> </div> </div> <p><a href="./references#CD003328-bbs2-0006" title="HamlynAN , LesnaM , RecordCO , SmithPA , PathFRC , WatsonAJ . Methionine and cysteamine in paracetamol overdose, prospective controlled trial of early therapy. Journal of International Medical Research1981;9:226‐31. ">Hamlyn 1981</a> found cysteamine and methionine to be equally as effective at reducing hepatotoxicity (OR not reported, OR for hepatotoxicity calculated using Fisher's exact test, OR 0.92, 95% CI 0.05 to 18.86, P = 1.0) (<a href="./references#CD003328-fig-0012" title="">Analysis 3.2</a>: OR 0.92, 95% CI 0.05 to 16.46). See <a href="./full#CD003328-tbl-0004">summary of findings Table 4</a>. </p> <p>One trial (52 participants) comparing cysteamine and dimercaprol found that cysteamine was superior to dimercaprol in terms of the severity of hepatic necrosis found on liver biopsy (<a href="./references#CD003328-bbs2-0007" title="HughesRD , GazzardBG , HanidMA , TrewbyPN , Murray‐LyonIM , DavisM , et al. Controlled trial of cysteamine and dimercaprol after paracetamol overdose. BMJ (Clinical Research Ed.)1977;2:1395. ">Hughes 1977</a>). However, no evidence of a difference in effect was found when comparison was made of peak AST concentrations with a peak AST of 722 IU/L versus 754 IU/L in those receiving cysteamine and dimercaprol (Wilcoxon's rank sum test P=NS) (<a href="./references#CD003328-fig-0014" title="">Analysis 4.2</a>: mean difference: ‐32.00 95%CI ‐126.33 to 62.33) see <a href="./full#CD003328-tbl-0003">summary of findings Table 3</a>. </p> </section> <section id="CD003328-sec-0097"> <h6 class="title">Adverse events</h6> <p>All trials reported that most participants given cysteamine had nausea and vomiting during its administration. Some participants also had severe headaches, one a transient truncal rash, and one developed severe malaise (<a href="./references#CD003328-bbs2-0006" title="HamlynAN , LesnaM , RecordCO , SmithPA , PathFRC , WatsonAJ . Methionine and cysteamine in paracetamol overdose, prospective controlled trial of early therapy. Journal of International Medical Research1981;9:226‐31. ">Hamlyn 1981</a>). Dimercaprol was given as a deep intramuscular injection, which all participants found painful; 9/26 participants developed severe abdominal pain (<a href="./references#CD003328-bbs2-0007" title="HughesRD , GazzardBG , HanidMA , TrewbyPN , Murray‐LyonIM , DavisM , et al. Controlled trial of cysteamine and dimercaprol after paracetamol overdose. BMJ (Clinical Research Ed.)1977;2:1395. ">Hughes 1977</a>). </p> </section> </section> <section id="CD003328-sec-0098"> <h5 class="title">Acetylcysteine</h5> <section id="CD003328-sec-0099"> <h6 class="title">Mortality</h6> <p>One trial (50 participants) found that intravenous acetylcysteine compared with placebo in people with paracetamol‐induced fulminant hepatic failure reduced mortality with a difference in survival of 28% (Chi<sup>2</sup> test utilised to assess difference in survival, P = 0.037; 95% CI for difference in survival 3% to 53%) (OR not reported, OR for mortality calculated using Fisher's exact test, OR 0.27, 95% CI 0.08 to 0.95; P = 0.07) (<a href="./references#CD003328-fig-0015" title="">Analysis 5.1</a>: Peto OR 0.29, 95% CI 0.09 to 0.94) (<a href="./references#CD003328-bbs2-0008" title="KeaysR , HarrisonPM , WendonJA , ForbesA , GoveC , AlexanderGJM , et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure. BMJ (Clinical Research Ed.)1991;303:1026‐9. ">Keays 1991</a>). As shown in <a href="#CD003328-fig-0005">Figure 5</a>, this effect was also not statistically significant in a Trial Sequential Analysis and the Trial Sequential Analysis‐adjusted CI ranged from 0.01 to 15.8. </p> <div class="figure" id="CD003328-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of acetylcysteine versus placebo on mortality. The diversity‐adjusted required information size (DARIS) is 375 participants based on a proportion of 80% with the outcome in the control group (Pc); a risk reduction of 20% (Peto OR: POR); an alpha (a) of 2.5%; a beta (b) of 20% (equivalent to a power of 80%); and an assumed diversity of 20%. As demonstrated the trial sequential monitoring boundaries for benefit, harm, or futility were crossed by the cumulative Z value." data-id="CD003328-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis of acetylcysteine versus placebo on mortality. The diversity‐adjusted required information size (DARIS) is 375 participants based on a proportion of 80% with the outcome in the control group (Pc); a risk reduction of 20% (Peto OR: POR); an alpha (a) of 2.5%; a beta (b) of 20% (equivalent to a power of 80%); and an assumed diversity of 20%. As demonstrated the trial sequential monitoring boundaries for benefit, harm, or futility were crossed by the cumulative Z value. </p> </div> </div> </div> <p>One trial (180 participants) found no difference between an initial intravenous dose of acetylcysteine administered over 15 minutes compared with administration for 60 minutes for mortality (OR for mortality not calculated by authors, <a href="./references#CD003328-fig-0016" title="">Analysis 6.1</a>: not estimable) (<a href="./references#CD003328-bbs2-0009" title="KerrF , DawsonA , WhyteIM , BuckleyN , MurrayL , GraudinsA , et al. The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N‐acetylcysteine. Annals of Emergency Medicine2005;45(4):402‐8. [MEDLINE: PMID: 15795719] ">Kerr 2005</a>). </p> </section> <section id="CD003328-sec-0100"> <h6 class="title">Hepatotoxicity</h6> <p>One trial (180 participants) found no difference between an initial intravenous dose of acetylcysteine administered over 15 minutes compared with administration for 60 minutes (<a href="./references#CD003328-bbs2-0009" title="KerrF , DawsonA , WhyteIM , BuckleyN , MurrayL , GraudinsA , et al. The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N‐acetylcysteine. Annals of Emergency Medicine2005;45(4):402‐8. [MEDLINE: PMID: 15795719] ">Kerr 2005</a>) (OR for hepatotoxicity not calculated by authors, OR for hepatotoxicity using Fisher's exact test, OR 1.31, 95% CI 0.39 to 4.56; P = 0.75) (<a href="./references#CD003328-fig-0017" title="">Analysis 6.2</a>: OR 1.34, 95% CI 0.39 to 4.56). </p> <p>One trial (222 participants) compared two different acetylcysteine regimens: a modified 12‐hour intravenous acetylcysteine regimen that had an initial lower loading dose given over two hours versus the standard 20.25‐hour schedule (<a href="./references#CD003328-bbs2-0002" title="BatemanDN , DearJW , ThanacoodyHK , ThomasSH , EddlestonM , SandilandsEA , et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet2014;383(9918):607‐704. [DOI: 10.1016/S0140‐6736(13)62062‐0] ">Bateman 2014</a>). Five participants developed hepatotoxicity, two allocated to the 12‐hour regimen versus three allocated to the 20.5‐hour regimen (OR not reported, calculated using Fisher's exact test, OR 0.67, 95% CI 0.12 to 3.33; P &gt; 0.99) (for comparison see <a href="./references#CD003328-fig-0020" title="">Analysis 7.2</a>: OR 0.67, 95% CI 0.11 to 4.08; which is less valid as we only had one trial). See <a href="./full#CD003328-tbl-0005">summary of findings Table 5</a>. </p> <p>One trial (66 participants) assessed oral acetylcysteine versus a standard 20.25‐hour intravenous acetylcysteine regimen and found no statistically significant difference in serum AST, ALT, bilirubin, and prothrombin time at 24, 48, and 72 hours but the numbers were small in both groups and the trial was not powered to show a difference in efficacy (<a href="./references#CD003328-bbs2-0001" title="ArefiM , BehnoushB , PourazizH , YousefinejadV . Comparison of oral and intravenous N‐acetylcysteine administration in the treatment of acetaminophen poisoning. Scientific Journal of Kurdistan University of Medical Sciences2013;18(2):36‐43. [] ">Arefi 2013</a>). See <a href="./full#CD003328-tbl-0006">summary of findings Table 6</a>. </p> </section> <section id="CD003328-sec-0101"> <h6 class="title">Adverse events</h6> <p>There were no adverse events to acetylcysteine reported. See <a href="./full#CD003328-tbl-0007">summary of findings Table 7</a>. </p> <p><a href="./references#CD003328-bbs2-0009" title="KerrF , DawsonA , WhyteIM , BuckleyN , MurrayL , GraudinsA , et al. The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N‐acetylcysteine. Annals of Emergency Medicine2005;45(4):402‐8. [MEDLINE: PMID: 15795719] ">Kerr 2005</a> found the incidence of drug‐related adverse events within two hours was 45% in the 15‐minute loading group versus 35% in the 60‐minute loading group (95% CI difference between the two groups ‐8% to 22% using the Chi<sup>2</sup> test; P = 0.36). However, there seemed to be a decrease in the overall number of participants with occurrence of any adverse events (75% in the 15‐minute loading group versus 61% in the 60‐minute loading group; OR not reported, calculated using Fisher's exact test OR 0.51, 95% CI 0.27 to 0.96; P = 0.05) (<a href="./references#CD003328-fig-0018" title="">Analysis 6.3</a>: OR 0.51, 95% CI 0.27 to 0.96). However, in a Trial Sequential Analysis this effect was not significant and the Trial Sequential Analysis‐adjusted CI ranged from 0.36 to 11.0 (<a href="#CD003328-fig-0006">Figure 6</a>). See <a href="./full#CD003328-tbl-0008">summary of findings Table 8</a>. </p> <div class="figure" id="CD003328-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of 15‐min infusion of acetylcysteine versus 60‐min infusion of acetylcysteine on any adverse event. The diversity‐adjusted required information size (DARIS) is 820 participants based on a proportion of 60% with the outcome in the control group (Pc); a risk reduction of 20%; an alpha (a) of 2.5%; a beta (b) of 20% (equivalent to a power of 80%); and an assumed diversity of 20%. As demonstrated the trial sequential monitoring boundaries for harm, benefit, or futility were crossed by the cumulative Z value." data-id="CD003328-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis of 15‐min infusion of acetylcysteine versus 60‐min infusion of acetylcysteine on any adverse event. The diversity‐adjusted required information size (DARIS) is 820 participants based on a proportion of 60% with the outcome in the control group (Pc); a risk reduction of 20%; an alpha (a) of 2.5%; a beta (b) of 20% (equivalent to a power of 80%); and an assumed diversity of 20%. As demonstrated the trial sequential monitoring boundaries for harm, benefit, or futility were crossed by the cumulative Z value. </p> </div> </div> </div> <p>One trial (222 participants) compared two different acetylcysteine regimens: a modified 12‐hour intravenous acetylcysteine regimen that had an initial lower loading dose given over two hours versus the standard 20.25‐hour schedule (<a href="./references#CD003328-bbs2-0002" title="BatemanDN , DearJW , ThanacoodyHK , ThomasSH , EddlestonM , SandilandsEA , et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet2014;383(9918):607‐704. [DOI: 10.1016/S0140‐6736(13)62062‐0] ">Bateman 2014</a>). The authors found that there was a reduction in the incidence of vomiting, retching, or need for antiemetics at two hours with the modified 12‐hour regimen (39/108 in the 12‐hour regimen group versus 71/109 in the 20.25‐hour regimen group; adjusted OR 0.26, 97.5% CI 0.13 to 0.52; P &lt; 0.0001) (<a href="./references#CD003328-fig-0021" title="">Analysis 7.3</a>: OR 0.30, 95% CI 0.17 to 0.53) (note difference as Analysis 7.2 was unadjusted). Anaphylactoid reactions were categorised as mild, moderate, and severe, with those receiving the shorter regimen having a reduced rate of reactions (58/108 in the 12‐hour regimen group versus 75/100 in the 20.25‐hour regimen group) (OR for anaphylactoid reactions were not calculated by authors, OR using Fisher's exact test, OR 0.39, 95% CI 0.22 to 0.71; P = 0.002) (<a href="./references#CD003328-fig-0023" title="">Analysis 7.5</a>: unadjusted OR 0.39, 95% CI 0.21 to 0.70). The number of severe anaphylactoid reactions was also reduced with the shorter modified regimen versus the standard regimen (5/108 in the 12‐hour regimen group versus 31/100 in the 20.25‐hour regimen group; adjusted common OR 0.23, 97.5% CI 0.12 to 0.43; P &lt; 0.0001). There was no difference in efficacy between the two regimens, but the trial was underpowered for this outcome. No deaths were recorded and accordingly, mortality could not be estimated (<a href="./references#CD003328-fig-0019" title="">Analysis 7.1</a>). </p> <p>One trial (66 participants) assessed oral acetylcysteine versus a standard 20.25‐hour intravenous acetylcysteine regimen (<a href="./references#CD003328-bbs2-0001" title="ArefiM , BehnoushB , PourazizH , YousefinejadV . Comparison of oral and intravenous N‐acetylcysteine administration in the treatment of acetaminophen poisoning. Scientific Journal of Kurdistan University of Medical Sciences2013;18(2):36‐43. [] ">Arefi 2013</a>). Nausea and hypotension were more prevalent in the oral compared with the intravenous acetylcysteine treatment group (nausea: 19/33 (57.6%) participants in the oral group versus 11/33 (33.3%) participants in the intravenous group; P = 0.04) (<a href="./references#CD003328-bbs2-0001" title="ArefiM , BehnoushB , PourazizH , YousefinejadV . Comparison of oral and intravenous N‐acetylcysteine administration in the treatment of acetaminophen poisoning. Scientific Journal of Kurdistan University of Medical Sciences2013;18(2):36‐43. [] ">Arefi 2013</a>). See <a href="./full#CD003328-tbl-0006">summary of findings Table 6</a>. </p> <p>One trial (40 participants) looked at a combination of intravenous plus oral acetylcysteine versus a standard 20.25‐hour intravenous acetylcysteine regimen (<a href="./references#CD003328-bbs2-0004" title="Eizadi‐MoodN , SabzghabaeeAM , SiadatS , YaraghiA , ShariatiM , GheshlaghiF , et al. Intravenous acetylcysteine versus oral and Intravenous acetylcysteine: does a combination therapy decrease side effects of acetylcysteine?. Pakistan Journal of Medical Sciences2013;29(1 Suppl):308‐11. [] ">Eizadi‐Mood 2013</a>). The main outcome was the rate of anaphylactoid reactions defined as nausea and vomiting, dyspnoea, and flushing. This trial post hoc excluded participants who vomited twice after oral acetylcysteine and did not include them in the intention‐to treat analysis. The authors found that 13.3% of participants who had intravenous plus oral acetylcysteine vomited versus 28.5% participants in the intravenous acetylcysteine group. However, adding the excluded 10 participants with vomiting increased this rate to 48% and reversed the conclusions of the trial (<a href="./references#CD003328-bbs2-0004" title="Eizadi‐MoodN , SabzghabaeeAM , SiadatS , YaraghiA , ShariatiM , GheshlaghiF , et al. Intravenous acetylcysteine versus oral and Intravenous acetylcysteine: does a combination therapy decrease side effects of acetylcysteine?. Pakistan Journal of Medical Sciences2013;29(1 Suppl):308‐11. [] ">Eizadi‐Mood 2013</a>). See <a href="./full#CD003328-tbl-0009">summary of findings Table 9</a>. </p> </section> </section> <section id="CD003328-sec-0102"> <h5 class="title">Ethylenediaminetetraacetic acid free acetylcysteine formulation</h5> <p>One trial registered by Cumberland Pharmaceuticals started in 2010 and was terminated due to lack of recruitment in 2013 (<a href="./references#CD003328-bbs2-0010" title="CumberlandPharmaceuticals . A multi‐center, double‐blind, randomized, controlled study to determine the efficacy and safety of a new formulation of acetylcysteine injection. clinicaltrials.gov/ct2/show/study/NCT01118663 Date first received: 4 August 2014. ">NCT01118663</a>). This trial compared the efficacy and safety of a new acetylcysteine protocol and a changed ethylenediaminetetraacetic acid free acetylcysteine formulation. The new protocol studied was 200 mg/kg of intravenous acetylcysteine in 1 L of fluid over four hours followed by 100 mg/kg in 1 L of fluid over 16 hours versus the standard three‐bag regimen, with an initial 60‐minute loading. The intended primary outcome was the incidence of hepatotoxicity. Secondary outcomes included adverse events and percentage of participants requiring continuation of therapy beyond 21 hours. Preliminary results were reported (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>); the trial recruited only 17 participants, with reported adverse event rate of 2/7 participants with the new protocol (four‐hour loading) group versus 1/10 participants from the three‐bag, 60‐minute loading group. The type and severity of these adverse events were not reported. Two participants in each group did not complete the course of intravenous acetylcysteine. The numbers from this trial were too small to analyse (<a href="./references#CD003328-bbs2-0010" title="CumberlandPharmaceuticals . A multi‐center, double‐blind, randomized, controlled study to determine the efficacy and safety of a new formulation of acetylcysteine injection. clinicaltrials.gov/ct2/show/study/NCT01118663 Date first received: 4 August 2014. ">NCT01118663</a>). </p> </section> </section> <section id="CD003328-sec-0103"> <h4 class="title">Extracorporeal treatment</h4> <section id="CD003328-sec-0104"> <h5 class="title">Mortality</h5> <p>One trial studied charcoal haemoperfusion versus conventional treatment (gastric lavage and fresh frozen plasma and intravenous fluids as clinically indicated) (16 participants) (<a href="./references#CD003328-bbs2-0005" title="GazzardBG , WillsonRA , WestonMJ , ThompsonRPH , WilliamsR . Charcoal haemoperfusion for paracetamol overdose. British Journal of Clinical Pharmacology1974;1:271‐5. ">Gazzard 1974a</a>). One participant allocated to the haemoperfusion group who had ingested 135 g of paracetamol died. There were no deaths in the control group. Accordingly, we found no benefit of charcoal haemoperfusion (<a href="./references#CD003328-bbs2-0005" title="GazzardBG , WillsonRA , WestonMJ , ThompsonRPH , WilliamsR . Charcoal haemoperfusion for paracetamol overdose. British Journal of Clinical Pharmacology1974;1:271‐5. ">Gazzard 1974a</a>) (number of deaths reported only, using Fisher's exact test, OR 3.40, 95% CI 0.12 to 96.8; P = 1.00) (<a href="./references#CD003328-fig-0024" title="">Analysis 8.1</a>: Peto OR 7.39, 95% CI 0.15 to 372.4). The Trial Sequential Analysis‐adjusted CI could not be calculated. See <a href="./full#CD003328-tbl-0010">summary of findings Table 10</a>. </p> </section> <section id="CD003328-sec-0105"> <h5 class="title">Plasma paracetamol concentration</h5> <p>One trial studied charcoal haemoperfusion versus conventional treatment (gastric lavage and fresh frozen plasma and intravenous fluids as clinically indicated) (16 participants) (<a href="./references#CD003328-bbs2-0005" title="GazzardBG , WillsonRA , WestonMJ , ThompsonRPH , WilliamsR . Charcoal haemoperfusion for paracetamol overdose. British Journal of Clinical Pharmacology1974;1:271‐5. ">Gazzard 1974a</a>). The mean cumulative amount of paracetamol removed was 1.4 g. </p> </section> </section> <section id="CD003328-sec-0106"> <h4 class="title">Additional safety data from quasi‐randomised trials</h4> <section id="CD003328-sec-0107"> <h5 class="title">Cimetidine</h5> <p>One quasi‐randomised trial studied cimetidine, with treatment allocation based on month enrolled (<a href="./references#CD003328-bbs2-0015" title="BurkhartKK , JancoN , KuligKW , RumackBH . Cimetidine as adjunctive treatment for acetaminophen overdose. Human &amp; Experimental Toxicology1995;14(3):299‐304. ">Burkhart 1995</a>). As this trial was quasi‐randomised, it could only be used to assess for the risk of harm. This trial found no adverse events. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003328-sec-0108" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003328-sec-0108"></div> <p>As identified in this review, there are very few randomised clinical trials investigating interventions for paracetamol poisoning, with all the evidence considered to be of low or very low quality. It is important to note that strict bias criteria were utilised and a trial was considered at low risk of bias only if all criteria were met. In many of these studies this was not feasible because, for example, blinding for interventions such as activated charcoal or length of acetylcysteine treatment were not possible. Current practices are often based on observational and non‐randomised studies, with current treatments seeming to have resulted in a decrease in mortality. The management of paracetamol poisoning varies widely between countries; for example, whether treatment is based on dose ingested or nomograms, which nomogram line is used, whether acetylcysteine should be administered orally or intravenously, and length of treatment. Most recommendations advise to measure a plasma paracetamol concentration, and if this level is above a chosen risk‐line, then acetylcysteine is advocated (<a href="./references#CD003328-bbs2-0061" title="DartR , ErdmanA , OlsonK , ChristiansonG , ManoguerraA , ChykaP , et al. Acetaminophen poisoning: an evidence‐based consensus guideline for out‐of‐hospital management. Clinical Toxicology2006;44(1):1‐18. [] ">Dart 2006</a>; <a href="./references#CD003328-bbs2-0060" title="DalyFF , FountainJS , MurrayL , GraudinsA , BuckleyNA , Panel of Australian and New Zealand clinical toxicologists. Guidelines for the management of paracetamol poisoning in Australia and New Zealand ‐ explanation and elaboration. A consensus statement from clinical toxicologists consulting to the Australasian poisons information centres. Medical Journal of Australia2008;188(5):296‐301. ">Daly 2008</a>). Many factors such as excess alcohol consumption, eating disorder, or use of enzyme‐inducing agents increase the risk of paracetamol hepatotoxicity, and these patient groups may need a lower threshold for treatment. However, most countries use a single nomogram line that has been lowered to essentially treat all people as high risk. Some guidelines suggest that liver biochemistry should be checked after treatment, and this is essential for symptomatic people, when treatment is delayed, with use of modified‐release formulation or large ingestions (<a href="./references#CD003328-bbs2-0131" title="ValeJA , ProudfootAT . Paracetamol (acetaminophen) poisoning. Lancet1995;346(8974):547‐52. ">Vale 1995</a>; <a href="./references#CD003328-bbs2-0054" title="ChiewAL , FountainJS , GraudinsA , IsbisterGK , ReithD , BuckleyNA . Summary statement: new guidelines for the management of paracetamol poisoning in Australia and New Zealand. Medical Journal of Australia2015;203(5):215‐8. ">Chiew 2015</a>). If the person has developed, or is at risk of developing, fulminant hepatic failure, acetylcysteine treatment has been suggested to be continued until recovery (<a href="./references#CD003328-bbs2-0138" title="WolfSJ , HeardK , SloanEP , JagodaAS . Clinical policy: critical issues in the management of patients presenting to the emergency department with acetaminophen overdose. Annals of Emergency Medicine2007;50:292‐313. ">Wolf 2007</a>; <a href="./references#CD003328-bbs2-0054" title="ChiewAL , FountainJS , GraudinsA , IsbisterGK , ReithD , BuckleyNA . Summary statement: new guidelines for the management of paracetamol poisoning in Australia and New Zealand. Medical Journal of Australia2015;203(5):215‐8. ">Chiew 2015</a>; <a href="./references#CD003328-bbs2-0142" title="YoonE , BabarA , ChoudharyM , KutnerM , PyrsopoulosN . Acetaminophen‐induced hepatotoxicity: a comprehensive uUpdate. Journal of Clinical and Translational Hepatology2016;4(2):131‐42. ">Yoon 2016</a>; <a href="./references#CD003328-bbs2-0078" title="HeardK , NewtonA . Paracetamol overdose. BMJ Best Practice: bestpractice.bmj.com last updated: 28 March 2017:1‐46. ">Heard 2017</a>). It should be noted that acetylcysteine or paracetamol overdose itself (or both) without evidence of liver injury may increase the INR, and management decisions should be based on the entire liver biochemistry (<a href="./references#CD003328-bbs2-0136" title="WhyteIM , BuckleyNA , ReithDM , GoodhewI , SeldonM , DawsonAH . Acetaminophen causes an increased international normalized ratio by reducing functional factor VII. Therapeutic Drug Monitoring2000;22(6):742‐8. ">Whyte 2000</a>; <a href="./references#CD003328-bbs2-0119" title="SchmidtLE , KnudsenTT , DalhoffK , BendtsenF . Effect of acetylcysteine on prothrombin index in paracetamol poisoning without hepatocellular injury. Lancet2002;360(9340):1151‐2. ">Schmidt 2002</a>). </p> <p>The methods used for decontamination include gastric lavage, activated charcoal, and ipecacuanha. The results from the one small randomised clinical trial were very low quality evidence that any of these measures can reduce the absorption of paracetamol, if given shortly after ingestion (<a href="./references#CD003328-bbs2-0011" title="UnderhillTJ , GreeneMK , DoveAF . A comparison of the efficacy of gastric lavage, ipecacuanha and activated charcoal in the emergency management of paracetamol overdose. Archives of Emergency Medicine1990;7:148‐54. ">Underhill 1990</a>). One well‐known complication from all the three interventions is aspiration pneumonia (<a href="./references#CD003328-bbs2-0093" title="LiisananttiJ , KaukorantaP , MartikainenM , Ala‐KokkoT . Aspiration pneumonia following severe self‐poisoning. Resuscitation2003;56(1):49‐53. [MEDLINE: PMID: 12505738] ">Liisanantti 2003</a>). However, randomised trials in overdose have reported no increase of adverse events in people receiving activated charcoal (<a href="./references#CD003328-bbs2-0017" title="CooperGM , LeCouteurDG , RichardsonD , BuckleyNA . A randomized clinical trial of activated charcoal for the routine management of oral drug overdose. QJM : Monthly Journal of the Association of Physicians2005;98(9):655‐60. [MEDLINE: PMID: 16040667] ">Cooper 2005</a>; <a href="./references#CD003328-bbs2-0067" title="EddlestonM , JuszczakE , BuckleyNA , SenarathnaL , MohamedF , DissanayakeW , et al. Multiple‐dose activated charcoal in acute self‐poisoning: a randomised controlled trial. Lancet2008;371(9612):579‐87. ">Eddleston 2008</a>). Position statements on drug poisonings indicate that serious adverse events seem to be fewer in people receiving activated charcoal compared to ipecacuanha and gastric lavage (<a href="./references#CD003328-bbs2-0131" title="ValeJA , ProudfootAT . Paracetamol (acetaminophen) poisoning. Lancet1995;346(8974):547‐52. ">Vale 1995</a>; <a href="./references#CD003328-bbs2-0089" title="KrenzelokEP , McGuiganM , LheurP , ManoguerraAS . Position paper: Ipecac syrup. Journal of Toxicology. Clinical Toxicology2004;42(2):133‐43. [MEDLINE: PMID: 15214617] ">Krenzelok 2004</a>; <a href="./references#CD003328-bbs2-0058" title="ChykaPA , SegerD , KrenzelokEP , ValeJA , American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists. Position paper: single‐dose activated charcoal. Clinical Toxicology2005;43(2):61‐87. [MEDLINE: PMID: 15822758] ">Chyka 2005</a>). Multiple observational and volunteer studies have investigated the effect of activated charcoal on paracetamol absorption (<a href="./references#CD003328-bbs2-0051" title="BuckleyNA , WhyteIM , O'ConnellDL , DawsonAH . Activated charcoal reduces the need for N‐acetylcysteine treatment after acetaminophen (paracetamol) overdose. Journal of Toxicology. Clinical Toxicology1999;37(6):753‐7. ">Buckley 1999a</a>; <a href="./references#CD003328-bbs2-0141" title="YeatesPJA , ThomasSHL . Effectiveness of delayed activated charcoal administration in simulated paracetamol (acetaminophen) overdose. British Journal of Clinical Pharmacology2000;49(1):11‐4. ">Yeates 2000</a>). These studies have shown that activated charcoal decreases the initial paracetamol concentration (<a href="./references#CD003328-bbs2-0051" title="BuckleyNA , WhyteIM , O'ConnellDL , DawsonAH . Activated charcoal reduces the need for N‐acetylcysteine treatment after acetaminophen (paracetamol) overdose. Journal of Toxicology. Clinical Toxicology1999;37(6):753‐7. ">Buckley 1999a</a>; <a href="./references#CD003328-bbs2-0066" title="DuffullSB , IsbisterGK . Predicting the requirement for N‐acetylcysteine in paracetamol poisoning from reported dose. Clinical Toxicology (Philadelphia, Pa.)2013;51(8):772‐6. ">Duffull 2013</a>; <a href="./references#CD003328-bbs2-0056" title="ChiewAL , IsbisterGK , KirbyKA , PageCB , ChanBSH , BuckleyNA . Massive paracetamol overdose: an observational study of the effect of activated charcoal and increased acetylcysteine dose (ATOM‐2). Clinical Toxicology (Philadelphia, Pa.)2017;55(10):1055‐65. ">Chiew 2017</a>). Accordingly, weak evidence indicated that activated charcoal is currently the best choice to prevent absorption of paracetamol. It appears most effective when given within two hours of ingestion, but the benefit may extend to four hours especially in larger overdoses (<a href="./references#CD003328-bbs2-0051" title="BuckleyNA , WhyteIM , O'ConnellDL , DawsonAH . Activated charcoal reduces the need for N‐acetylcysteine treatment after acetaminophen (paracetamol) overdose. Journal of Toxicology. Clinical Toxicology1999;37(6):753‐7. ">Buckley 1999a</a>; <a href="./references#CD003328-bbs2-0056" title="ChiewAL , IsbisterGK , KirbyKA , PageCB , ChanBSH , BuckleyNA . Massive paracetamol overdose: an observational study of the effect of activated charcoal and increased acetylcysteine dose (ATOM‐2). Clinical Toxicology (Philadelphia, Pa.)2017;55(10):1055‐65. ">Chiew 2017</a>). </p> <p>Various antidotes for paracetamol poisoning have been studied, all in small randomised trials (<a href="./references#CD003328-bbs2-0003" title="DouglasAP , HamlynAN , JamesO . Controlled trial of cysteamine in treatment of acute paracetamol poisoning. Lancet1976;2:111‐5. ">Douglas 1976a</a>; <a href="./references#CD003328-bbs2-0007" title="HughesRD , GazzardBG , HanidMA , TrewbyPN , Murray‐LyonIM , DavisM , et al. Controlled trial of cysteamine and dimercaprol after paracetamol overdose. BMJ (Clinical Research Ed.)1977;2:1395. ">Hughes 1977</a>; <a href="./references#CD003328-bbs2-0006" title="HamlynAN , LesnaM , RecordCO , SmithPA , PathFRC , WatsonAJ . Methionine and cysteamine in paracetamol overdose, prospective controlled trial of early therapy. Journal of International Medical Research1981;9:226‐31. ">Hamlyn 1981</a>; <a href="./references#CD003328-bbs2-0008" title="KeaysR , HarrisonPM , WendonJA , ForbesA , GoveC , AlexanderGJM , et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure. BMJ (Clinical Research Ed.)1991;303:1026‐9. ">Keays 1991</a>). Acetylcysteine seems preferable to placebo/supportive treatment, dimercaprol, and cysteamine, in terms of adverse effects. However, a randomised clinical trial has not directly compared these treatments in terms of rates of acute liver injury or mortality. Acetylcysteine and methionine have similarly not been compared in a randomised clinical trial; however, the previous Cochrane Review concluded that both drugs demonstrated comparable effectiveness at decreasing the risk of hepatotoxicity (<a href="./references#CD003328-bbs2-0144" title="BrokJ , BuckleyN , GluudC . Interventions for paracetamol (acetaminophen) overdose. Cochrane Database of Systematic Reviews2006, Issue 2. [; DOI: 10.1002/14651858.CD003328.pub2; JC‐‐NLM: Journal ID:100909747] ">Brok 2006</a>). The initial acetylcysteine study was an observational study that compared intravenous acetylcysteine (100 participants) to three groups, intravenous cysteamine (40 participants), intravenous methionine (20 participants), or supportive treatment alone (57 participants) (<a href="./references#CD003328-bbs2-0107" title="PrescottLF , IllinngworthRN , ChrichleyJAJ , StewartMJ , AdamRD , ProudfootAT . Intravenous N‐acetylcysteine: the treatment of choice for paracetamol poisoning. British Medical Journal1979;2:1097‐100. ">Prescott 1979</a>). In this study, the comparison antidote groups were historical control groups treated three years earlier and supportive care groups 10 years earlier. They found intravenous acetylcysteine was highly effective in protecting against severe liver damage, renal failure, and death after paracetamol overdosage when given within eight to 10 hours of ingestion. Since this study was published, acetylcysteine has been recommended for paracetamol poisoning in most countries (<a href="./references#CD003328-bbs2-0138" title="WolfSJ , HeardK , SloanEP , JagodaAS . Clinical policy: critical issues in the management of patients presenting to the emergency department with acetaminophen overdose. Annals of Emergency Medicine2007;50:292‐313. ">Wolf 2007</a>; <a href="./references#CD003328-bbs2-0054" title="ChiewAL , FountainJS , GraudinsA , IsbisterGK , ReithD , BuckleyNA . Summary statement: new guidelines for the management of paracetamol poisoning in Australia and New Zealand. Medical Journal of Australia2015;203(5):215‐8. ">Chiew 2015</a>; <a href="./references#CD003328-bbs2-0142" title="YoonE , BabarA , ChoudharyM , KutnerM , PyrsopoulosN . Acetaminophen‐induced hepatotoxicity: a comprehensive uUpdate. Journal of Clinical and Translational Hepatology2016;4(2):131‐42. ">Yoon 2016</a>; <a href="./references#CD003328-bbs2-0078" title="HeardK , NewtonA . Paracetamol overdose. BMJ Best Practice: bestpractice.bmj.com last updated: 28 March 2017:1‐46. ">Heard 2017</a>). Historical data showed that the overall mortality rate has dropped from 3% (all poisonings (<a href="./references#CD003328-bbs2-0059" title="ClarkR , BorirakchanyavatV , DavidsonAR , ThompsonRP , WiddopB , GouldingR , et al. Hepatic damage and death from overdose of paracetamol. Lancet1973;1(7794):66‐70. ">Clark 1973</a>) or 5% (all above the probable risk‐line (<a href="./references#CD003328-bbs2-0107" title="PrescottLF , IllinngworthRN , ChrichleyJAJ , StewartMJ , AdamRD , ProudfootAT . Intravenous N‐acetylcysteine: the treatment of choice for paracetamol poisoning. British Medical Journal1979;2:1097‐100. ">Prescott 1979</a>) to 0.4% in the 1980s after the introduction of acetylcysteine (<a href="./references#CD003328-bbs2-0073" title="GunnellD , HawtonK , MurrayV , GarnierR , BismuthC , FaggJ , et al. Use of paracetamol for suicide and non‐fatal poisoning in the UK and France: are restrictions on availability justified?. Journal of Epidemiology and Community Health1997;51:175‐9. ">Gunnell 1997</a>)). Similarly, the rates of acute liver injury due to paracetamol toxicity have declined since the routine use of acetylcysteine. The major risk factor for developing acute liver injury following paracetamol ingestion was delayed time to treatment with acetylcysteine (<a href="./references#CD003328-bbs2-0107" title="PrescottLF , IllinngworthRN , ChrichleyJAJ , StewartMJ , AdamRD , ProudfootAT . Intravenous N‐acetylcysteine: the treatment of choice for paracetamol poisoning. British Medical Journal1979;2:1097‐100. ">Prescott 1979</a>; <a href="./references#CD003328-bbs2-0124" title="SmilksteinMJ , KnappGL , KuligKW , RumackBH . Efficacy of oral N‐acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). New England Journal of Medicine1988;319(24):1557‐62. ">Smilkstein 1988</a>). Observational studies and meta‐analyses continue to show similar results with rates of hepatotoxicity reported in people receiving acetylcysteine treatment within eight hours ranging from 0% to 6% compared to people treated more than eight to 10 hours postingestion of 8% to 50% (<a href="./references#CD003328-bbs2-0014" title="BuckleyNA , WhyteIM , O'ConnellDL , DawsonAH . Oral or intravenous N‐acetylcysteine: which is the treatment of choice for acetaminophen (paracetamol) poisoning?. Journal of Toxicology. Clinical Toxicology1999;37(6):759‐67. [; JC‐‐NLM: Journal ID:kan, 8213460] ">Buckley 1999b</a>; <a href="./references#CD003328-bbs2-0009" title="KerrF , DawsonA , WhyteIM , BuckleyN , MurrayL , GraudinsA , et al. The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N‐acetylcysteine. Annals of Emergency Medicine2005;45(4):402‐8. [MEDLINE: PMID: 15795719] ">Kerr 2005</a>; <a href="./references#CD003328-bbs2-0144" title="BrokJ , BuckleyN , GluudC . Interventions for paracetamol (acetaminophen) overdose. Cochrane Database of Systematic Reviews2006, Issue 2. [; DOI: 10.1002/14651858.CD003328.pub2; JC‐‐NLM: Journal ID:100909747] ">Brok 2006</a>; <a href="./references#CD003328-bbs2-0065" title="DoyonS , Klein‐SchwartzW . Hepatotoxicity despite early administration of intravenous N‐acetylcysteine for acute acetaminophen overdose. Academic Emergency Medicine2009;16(1):34‐9. ">Doyon 2009</a>; <a href="./references#CD003328-bbs2-0072" title="GreenJL , HeardKJ , ReynoldsKM , AlbertD . Oral and intravenous acetylcysteine for treatment of acetaminophen toxicity: a systematic review and meta‐analysis. Western Journal of Emergency Medicine2013;14(3):218‐26. ">Green 2013</a>; <a href="./references#CD003328-bbs2-0077" title="HeardK , RumackBH , GreenJL , Bucher‐BartelsonB , HeardS , BronsteinAC , et al. A single‐arm clinical trial of a 48‐hour intravenous N‐acetylcysteine protocol for treatment of acetaminophen poisoning. Clinical Toxicology2014;52:512‐8. ">Heard 2014</a>). From the one small randomised clinical trial, survival among people with paracetamol‐induced fulminant hepatic failure was higher if treated with acetylcysteine (<a href="./references#CD003328-bbs2-0008" title="KeaysR , HarrisonPM , WendonJA , ForbesA , GoveC , AlexanderGJM , et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure. BMJ (Clinical Research Ed.)1991;303:1026‐9. ">Keays 1991</a>). </p> <p>Acetylcysteine can be administered orally or intravenously. Two small studies in this review compared oral to intravenous acetylcysteine; however, both were at high risk of bias (<a href="./references#CD003328-bbs2-0001" title="ArefiM , BehnoushB , PourazizH , YousefinejadV . Comparison of oral and intravenous N‐acetylcysteine administration in the treatment of acetaminophen poisoning. Scientific Journal of Kurdistan University of Medical Sciences2013;18(2):36‐43. [] ">Arefi 2013</a>; <a href="./references#CD003328-bbs2-0004" title="Eizadi‐MoodN , SabzghabaeeAM , SiadatS , YaraghiA , ShariatiM , GheshlaghiF , et al. Intravenous acetylcysteine versus oral and Intravenous acetylcysteine: does a combination therapy decrease side effects of acetylcysteine?. Pakistan Journal of Medical Sciences2013;29(1 Suppl):308‐11. [] ">Eizadi‐Mood 2013</a>). One meta‐analysis of over 5000 participants admitted with a paracetamol overdose compared oral to intravenous acetylcysteine and showed similar rates of hepatotoxicity in (12.6% with oral versus 13.2% with intravenous). Treatment delays (beyond 10 hours) were associated with the highest risk of liver injury (<a href="./references#CD003328-bbs2-0072" title="GreenJL , HeardKJ , ReynoldsKM , AlbertD . Oral and intravenous acetylcysteine for treatment of acetaminophen toxicity: a systematic review and meta‐analysis. Western Journal of Emergency Medicine2013;14(3):218‐26. ">Green 2013</a>). Both oral and intravenous acetylcysteine were associated with adverse effects. These reactions range from mild to severe symptoms and include rash, nausea, vomiting, angioedema, tachycardia, bronchospasm, hypotension, and death (<a href="./references#CD003328-bbs2-0095" title="MantTG , TempowskiJH , VolansGN , TalbotJC . Adverse reactions to acetylcysteine and effects of overdose. British Medical Journal (Clinical Research Ed.)1984;289(6439):217‐9. [PMID: 6234965] ">Mant 1984</a>; <a href="./references#CD003328-bbs2-0045" title="BaileyB , McGuiganMA . Management of anaphylactoid reactions to intravenous N‐acetylcysteine. Annals of Emergency Medicine1998;31:710‐5. ">Bailey 1998</a>; <a href="./references#CD003328-bbs2-0118" title="SchmidtLE , DalhoffK . Risk factors in the development of adverse reactions to N‐acetylcysteine in patients with paracetamol poisoning. British Journal of Pharmacology2001;51(1):87‐91. ">Schmidt 2001</a>; <a href="./references#CD003328-bbs2-0086" title="KaoLW , KirkMA , FurbeeRB , MehtaNH , SkinnerJR , BrizendineEJ . What is the rate of adverse events after oral N‐acetylcysteine administered by the intravenous route to patients with suspected acetaminophen poisoning?. Annals of Emergency Medicine2003;42(6):741‐50. ">Kao 2003</a>). The most common reactions from intravenous acetylcysteine are nausea, vomiting, and cutaneous systemic hypersensitivity reactions (<a href="./references#CD003328-bbs2-0115" title="SandilandsEA , BatemanDN . Adverse reactions associated with acetylcysteine. Clinical Toxicology (Philadelphia, Pa.)2009;47(2):81‐8. ">Sandilands 2009</a>). Oral acetylcysteine administration often results in rash, nausea, vomiting, and abdominal pain. The rates of adverse reactions vary greatly between observational studies. Reported rates depend on whether it was a prospective or retrospective study and which adverse effects were measured (e.g. total versus gastrointestinal versus systemic hypersensitivity reactions). There are many observational studies of acetylcysteine, a review that examined some of these larger studies reported that rates of adverse effects from acetylcysteine varied from 8.5% to 77% (<a href="./references#CD003328-bbs2-0055" title="ChiewAL , IsbisterGK , DuffullSB , BuckleyNA . Evidence for the changing regimens of acetylcysteine. British Journal of Pharmacology2016;81(3):471‐81. [DOI: 10.1111/bcp.12789] ">Chiew 2016</a>). </p> <p>Trials of acetylcysteine have looked at different regimens to decrease the rate of adverse effects. There are four trials looking at different acetylcysteine regimens compared with the standard three‐bag intravenous acetylcysteine regimen (<a href="./references#CD003328-bbs2-0009" title="KerrF , DawsonA , WhyteIM , BuckleyN , MurrayL , GraudinsA , et al. The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N‐acetylcysteine. Annals of Emergency Medicine2005;45(4):402‐8. [MEDLINE: PMID: 15795719] ">Kerr 2005</a>; <a href="./references#CD003328-bbs2-0001" title="ArefiM , BehnoushB , PourazizH , YousefinejadV . Comparison of oral and intravenous N‐acetylcysteine administration in the treatment of acetaminophen poisoning. Scientific Journal of Kurdistan University of Medical Sciences2013;18(2):36‐43. [] ">Arefi 2013</a>; <a href="./references#CD003328-bbs2-0004" title="Eizadi‐MoodN , SabzghabaeeAM , SiadatS , YaraghiA , ShariatiM , GheshlaghiF , et al. Intravenous acetylcysteine versus oral and Intravenous acetylcysteine: does a combination therapy decrease side effects of acetylcysteine?. Pakistan Journal of Medical Sciences2013;29(1 Suppl):308‐11. [] ">Eizadi‐Mood 2013</a>; <a href="./references#CD003328-bbs2-0002" title="BatemanDN , DearJW , ThanacoodyHK , ThomasSH , EddlestonM , SandilandsEA , et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet2014;383(9918):607‐704. [DOI: 10.1016/S0140‐6736(13)62062‐0] ">Bateman 2014</a>). The primary outcomes of these trials were adverse effects of treatments and none were powered to look at efficacy. Various observational studies have looked at differing acetylcysteine regimens to decrease the rate of adverse reactions or decrease drug administration errors but again these were not powered to look at efficacy (<a href="./references#CD003328-bbs2-0055" title="ChiewAL , IsbisterGK , DuffullSB , BuckleyNA . Evidence for the changing regimens of acetylcysteine. British Journal of Pharmacology2016;81(3):471‐81. [DOI: 10.1111/bcp.12789] ">Chiew 2016</a>). Furthermore, there has been increasing concerns that the standard intravenous acetylcysteine doses are inadequate in people with very high initial paracetamol concentrations, who require higher doses of acetylcysteine (<a href="./references#CD003328-bbs2-0114" title="RumackBH , BatemanDN . Acetaminophen and acetylcysteine dose and duration: past, present and future. Clinical Toxicology2012;50:91‐8. ">Rumack 2012</a>; <a href="./references#CD003328-bbs2-0055" title="ChiewAL , IsbisterGK , DuffullSB , BuckleyNA . Evidence for the changing regimens of acetylcysteine. British Journal of Pharmacology2016;81(3):471‐81. [DOI: 10.1111/bcp.12789] ">Chiew 2016</a>). People with increased paracetamol concentration on presentation are at higher risk of liver injury even when intravenous acetylcysteine is administered early (<a href="./references#CD003328-bbs2-0053" title="CairneyDG , BeckwithHK , Al‐HouraniK , EddlestonM , BatemanDN , DearJW . Plasma paracetamol concentration at hospital presentation has a dose‐dependent relationship with liver injury despite prompt treatment with intravenous acetylcysteine. Clinical Toxicology (Philadelphia, Pa.)2016;54(5):405‐10. ">Cairney 2016</a>). Further studies are warranted to compare efficacy between different treatment regimens looking at both the dose and rate of acetylcysteine infusions. </p> <p>Only one very small study looked at extracorporeal treatment, which showed no benefit from charcoal haemoperfusion (<a href="./references#CD003328-bbs2-0005" title="GazzardBG , WillsonRA , WestonMJ , ThompsonRPH , WilliamsR . Charcoal haemoperfusion for paracetamol overdose. British Journal of Clinical Pharmacology1974;1:271‐5. ">Gazzard 1974a</a>). The Extracorporeal Treatments in Poisoning (EXTRIP) Workgroup, published recommendations in 2014, regarding paracetamol and extracorporeal treatment. EXTRIP searched for randomised clinical trials, observational studies, case reports, case series, and pharmacokinetic studies. From these, the EXTRIP panel concluded that paracetamol was dialysable and suggested extracorporeal treatments could be considered in cases of severe paracetamol poisoning, defined by paracetamol level, acidosis, or coma and also depending on antidote availability. They concluded that intermittent haemodialysis is the preferred extracorporeal treatment in people with paracetamol poisoning. Intermittent haemoperfusion or continuous renal replacement modalities are valid alternatives if intermittent haemodialysis is not available. Furthermore, acetylcysteine treatment should be continued during extracorporeal treatment at an increased rate (<a href="./references#CD003328-bbs2-0070" title="GosselinS , JuurlinkDN , KielsteinJT , GhannoumM , LavergneV , NolinTD , EXTRIP Workgroup. Extracorporeal treatment for acetaminophen poisoning: recommendations from the EXTRIP workgroup. Clinical Toxicology (Philadelphia, Pa.)2014;52(852):856‐67. ">Gosselin 2014</a>). </p> <p>Since the late‐1980s, survival from acute liver failure from any cause has markedly improved, with a significant improvement in paracetamol‐induced acute liver failure. This is because of improved intensive care, earlier illness recognition, and use of emergency liver transplantation when required (<a href="./references#CD003328-bbs2-0047" title="BernalW , HyyrylainenA , GeraA , AudimoolamVK , McPhailMJW , AuzingerG , et al. Lessons from look‐back in acute liver failure? A single centre experience of 3300 patients. Journal of Hepatology2013;59:74‐80. ">Bernal 2013</a>). Over this same period, transplant‐free survival in people with acute liver failure secondary to paracetamol has improved to nearly 70% (<a href="./references#CD003328-bbs2-0110" title="ReubenA , TillmanH , FontanaRJ , DavernT , McGuireB , StravitzRT , et al. Outcomes in adults with acute liver failure between 1998 and 2013: an observational cohort study. Annals of Internal Medicine2016;164(11):724‐32. ">Reuben 2016</a>). However, in people who develop irreversible liver damage, the ultimate treatment is liver transplantation. </p> <p>There are various limitations in this review. First, for most interventions, there were only one or two small trials and most trials were at high risk of bias and at high risk of play of chance. Hence no greater certainty about treatment effects could be determined through meta‐analysis. Second, the interventions studied varied greatly and even those studying similar interventions varied in rates and mode of administration of the drugs meaning comparisons between various intervention options could not be made. Heterogeneity was high due to the varying interventions and participants. Much of the protocol outlined in the methods could not be applied to the studies included. </p> <p>The results of this systematic review highlighted a lack of randomised clinical trials on interventions for paracetamol overdose, despite it being a very common drug for poisoning worldwide. Most of the included randomised clinical trials were small and some trials assessed interventions not used in the 21st century. Furthermore, no randomised clinical trials investigated the efficacy of acetylcysteine versus commonly available oral antidotes such as methionine. It is unlikely that a trial will be conducted comparing acetylcysteine with placebo, except perhaps in very low risk people. Research has focused on testing different acetylcysteine regimens with the aim to lower adverse effects or to shorten the duration of treatment, while maintaining or improving outcomes. </p> <section id="CD003328-sec-0109"> <h3 class="title" id="CD003328-sec-0109">Summary of main results</h3> <p>The interventions to treat paracetamol poisoning can be divided into two main groups, those treatments that decrease serum paracetamol concentration, either by decontamination or by extracorporeal treatments and antidotes that decrease the amount or detoxify the toxic metabolite NAPQI. </p> <section id="CD003328-sec-0110"> <h4 class="title">Activated charcoal, gastric lavage and ipecacuanha</h4> <p>One randomised clinical trial found activated charcoal to be more effective than gastric lavage, ipecacuanha, or no intervention in preventing the absorption of paracetamol (<a href="./references#CD003328-bbs2-0011" title="UnderhillTJ , GreeneMK , DoveAF . A comparison of the efficacy of gastric lavage, ipecacuanha and activated charcoal in the emergency management of paracetamol overdose. Archives of Emergency Medicine1990;7:148‐54. ">Underhill 1990</a>). There were various limitations to this trial. </p> </section> <section id="CD003328-sec-0111"> <h4 class="title">Antidotes</h4> <section id="CD003328-sec-0112"> <h5 class="title">Cysteamine, methionine, and dimercaprol</h5> <p>Two randomised trials found methionine or cysteamine treatment resulted in lower AST concentrations and less hepatic necrosis on liver biopsy when compared with no intervention (<a href="./references#CD003328-bbs2-0003" title="DouglasAP , HamlynAN , JamesO . Controlled trial of cysteamine in treatment of acute paracetamol poisoning. Lancet1976;2:111‐5. ">Douglas 1976a</a>; <a href="./references#CD003328-bbs2-0006" title="HamlynAN , LesnaM , RecordCO , SmithPA , PathFRC , WatsonAJ . Methionine and cysteamine in paracetamol overdose, prospective controlled trial of early therapy. Journal of International Medical Research1981;9:226‐31. ">Hamlyn 1981</a>). There was no difference between the two antidotes in one trial (<a href="./references#CD003328-bbs2-0006" title="HamlynAN , LesnaM , RecordCO , SmithPA , PathFRC , WatsonAJ . Methionine and cysteamine in paracetamol overdose, prospective controlled trial of early therapy. Journal of International Medical Research1981;9:226‐31. ">Hamlyn 1981</a>), in terms of peak serum AST and rates of hepatic necrosis. In a further trial, cysteamine was superior to dimercaprol in terms of the severity of hepatic necrosis found on liver biopsy (<a href="./references#CD003328-bbs2-0007" title="HughesRD , GazzardBG , HanidMA , TrewbyPN , Murray‐LyonIM , DavisM , et al. Controlled trial of cysteamine and dimercaprol after paracetamol overdose. BMJ (Clinical Research Ed.)1977;2:1395. ">Hughes 1977</a>). Overall, cysteamine therapy was associated with a high rate of nausea and vomiting. There were few adverse events in participants given methionine and dimercaprol. </p> </section> <section id="CD003328-sec-0113"> <h5 class="title">Acetylcysteine</h5> <p>One randomised clinical trial found that intravenous acetylcysteine increased survival in participants with paracetamol‐induced fulminant hepatic failure compared with placebo (<a href="./references#CD003328-bbs2-0008" title="KeaysR , HarrisonPM , WendonJA , ForbesA , GoveC , AlexanderGJM , et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure. BMJ (Clinical Research Ed.)1991;303:1026‐9. ">Keays 1991</a>). However, no randomised trials have assessed the effect of acetylcysteine in the acute treatment of paracetamol overdose. Four completed randomised clinical trials have studied differing regimens of acetylcysteine administration to decrease rates of adverse events but none of these were powered for efficacy (<a href="./references#CD003328-bbs2-0009" title="KerrF , DawsonA , WhyteIM , BuckleyN , MurrayL , GraudinsA , et al. The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N‐acetylcysteine. Annals of Emergency Medicine2005;45(4):402‐8. [MEDLINE: PMID: 15795719] ">Kerr 2005</a>; <a href="./references#CD003328-bbs2-0001" title="ArefiM , BehnoushB , PourazizH , YousefinejadV . Comparison of oral and intravenous N‐acetylcysteine administration in the treatment of acetaminophen poisoning. Scientific Journal of Kurdistan University of Medical Sciences2013;18(2):36‐43. [] ">Arefi 2013</a>; <a href="./references#CD003328-bbs2-0004" title="Eizadi‐MoodN , SabzghabaeeAM , SiadatS , YaraghiA , ShariatiM , GheshlaghiF , et al. Intravenous acetylcysteine versus oral and Intravenous acetylcysteine: does a combination therapy decrease side effects of acetylcysteine?. Pakistan Journal of Medical Sciences2013;29(1 Suppl):308‐11. [] ">Eizadi‐Mood 2013</a>; <a href="./references#CD003328-bbs2-0002" title="BatemanDN , DearJW , ThanacoodyHK , ThomasSH , EddlestonM , SandilandsEA , et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet2014;383(9918):607‐704. [DOI: 10.1016/S0140‐6736(13)62062‐0] ">Bateman 2014</a>). One trial was abandoned because of lack of enrolment (<a href="./references#CD003328-bbs2-0010" title="CumberlandPharmaceuticals . A multi‐center, double‐blind, randomized, controlled study to determine the efficacy and safety of a new formulation of acetylcysteine injection. clinicaltrials.gov/ct2/show/study/NCT01118663 Date first received: 4 August 2014. ">NCT01118663</a>). </p> </section> </section> <section id="CD003328-sec-0114"> <h4 class="title">Extracorporeal treatments</h4> <p>The randomised clinical trial found involved haemoperfusion, we found no evidence to support or refute haemoperfusion for paracetamol overdose. </p> </section> <section id="CD003328-sec-0115"> <h4 class="title">Acute hepatic failure</h4> <p>Most interventions used to treat acute fulminant liver failure were not investigated in this review, but, based on one small trial, it appeared that acetylcysteine administration improved survival in participants with fulminant hepatic failure from paracetamol (<a href="./references#CD003328-bbs2-0008" title="KeaysR , HarrisonPM , WendonJA , ForbesA , GoveC , AlexanderGJM , et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure. BMJ (Clinical Research Ed.)1991;303:1026‐9. ">Keays 1991</a>). </p> </section> <section id="CD003328-sec-0116"> <h4 class="title">Children</h4> <p>There was less evidence on how to manage children who unintentionally ingest paracetamol. Children are rarely able to tell how much and when they have ingested the drug. Furthermore, the applicability of the recommended treatment line in young children has never been proven due to the paucity of data (<a href="./references#CD003328-bbs2-0131" title="ValeJA , ProudfootAT . Paracetamol (acetaminophen) poisoning. Lancet1995;346(8974):547‐52. ">Vale 1995</a>). </p> </section> </section> <section id="CD003328-sec-0117"> <h3 class="title" id="CD003328-sec-0117">Overall completeness and applicability of evidence</h3> <p>This review looked at many different treatment options for paracetamol overdose, each based on only one or very few randomised clinical trials and the quality of the evidence was found to be low or very low and incomplete. Most of the current recommendations for the treatment of paracetamol overdose are based on observational studies. </p> </section> <section id="CD003328-sec-0118"> <h3 class="title" id="CD003328-sec-0118">Quality of the evidence</h3> <p>In the 11 trials studied, the majority had multiple domains at high risks of bias (systematic errors, i.e. overestimation of benefits and underestimation of harms) as well as very small number of participants giving high risks of play of chance (random errors) and multiple items of high risks of bias. Thus, the quality of the evidence was assessed to be low or very low. </p> </section> <section id="CD003328-sec-0119"> <h3 class="title" id="CD003328-sec-0119">Potential biases in the review process</h3> <p>NB is an author on one of the trials included in this review (<a href="./references#CD003328-bbs2-0009" title="KerrF , DawsonA , WhyteIM , BuckleyN , MurrayL , GraudinsA , et al. The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N‐acetylcysteine. Annals of Emergency Medicine2005;45(4):402‐8. [MEDLINE: PMID: 15795719] ">Kerr 2005</a>). This risk of bias was minimised as other review authors determined if it could be included and assess risk of bias and extracted data. </p> </section> <section id="CD003328-sec-0120"> <h3 class="title" id="CD003328-sec-0120">Agreements and disagreements with other studies or reviews</h3> <p>We are not aware of any other systematic review of paracetamol overdose that covered all treatment options, besides the earlier versions of this review and the <i>BMJ Clinical Evidence</i> abbreviated reviews (<a href="./references#CD003328-bbs2-0104" title="ParkBK , DearJW , AntoineDJ . Paracetamol (acetaminophen) poisoning. BMJ Clinical Evidence2015;2015:pii: 2101. ">Park 2015</a>). The conclusions from the later review were broadly in line with those of this review. The findings of this review were not in conflict with existing guidelines including acetylcysteine in people at risk of hepatotoxicity or established acute liver injury (<a href="./references#CD003328-bbs2-0092" title="LeeWM , LarsonAM , Todd StravitzR . AASLD position paper: the management of acute liver failure: update 2011. www.aasld.org/practiceguidelines/Documents/AcuteLiverFailureUpdate2011.pdf(accessed June 2017). ">Lee 2011</a>; <a href="./references#CD003328-bbs2-0054" title="ChiewAL , FountainJS , GraudinsA , IsbisterGK , ReithD , BuckleyNA . Summary statement: new guidelines for the management of paracetamol poisoning in Australia and New Zealand. Medical Journal of Australia2015;203(5):215‐8. ">Chiew 2015</a>; <a href="./references#CD003328-bbs2-0078" title="HeardK , NewtonA . Paracetamol overdose. BMJ Best Practice: bestpractice.bmj.com last updated: 28 March 2017:1‐46. ">Heard 2017</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003328-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow chart: search strategy and results." data-id="CD003328-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow chart: search strategy and results.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003328-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003328-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of cysteamine versus control on hepatotoxicity defined as aspartate aminotransferase (AST) above 1000 IU/L. The diversity‐adjusted required information size (DARIS) was 982 participants based on a proportion of 53% with the outcome in the control group (Pc); a risk reduction of 20%; an alpha (a) of 2.5%; a beta (b) of 20% (equivalent to a power of 80%); and an assumed diversity of 20%. As demonstrated the trial sequential monitoring boundaries for benefit, harm, or futility were crossed by the cumulative Z value." data-id="CD003328-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Trial Sequential Analysis of cysteamine versus control on hepatotoxicity defined as aspartate aminotransferase (AST) above 1000 IU/L. The diversity‐adjusted required information size (DARIS) was 982 participants based on a proportion of 53% with the outcome in the control group (Pc); a risk reduction of 20%; an alpha (a) of 2.5%; a beta (b) of 20% (equivalent to a power of 80%); and an assumed diversity of 20%. As demonstrated the trial sequential monitoring boundaries for benefit, harm, or futility were crossed by the cumulative Z value. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of acetylcysteine versus placebo on mortality. The diversity‐adjusted required information size (DARIS) is 375 participants based on a proportion of 80% with the outcome in the control group (Pc); a risk reduction of 20% (Peto OR: POR); an alpha (a) of 2.5%; a beta (b) of 20% (equivalent to a power of 80%); and an assumed diversity of 20%. As demonstrated the trial sequential monitoring boundaries for benefit, harm, or futility were crossed by the cumulative Z value." data-id="CD003328-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Trial Sequential Analysis of acetylcysteine versus placebo on mortality. The diversity‐adjusted required information size (DARIS) is 375 participants based on a proportion of 80% with the outcome in the control group (Pc); a risk reduction of 20% (Peto OR: POR); an alpha (a) of 2.5%; a beta (b) of 20% (equivalent to a power of 80%); and an assumed diversity of 20%. As demonstrated the trial sequential monitoring boundaries for benefit, harm, or futility were crossed by the cumulative Z value. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of 15‐min infusion of acetylcysteine versus 60‐min infusion of acetylcysteine on any adverse event. The diversity‐adjusted required information size (DARIS) is 820 participants based on a proportion of 60% with the outcome in the control group (Pc); a risk reduction of 20%; an alpha (a) of 2.5%; a beta (b) of 20% (equivalent to a power of 80%); and an assumed diversity of 20%. As demonstrated the trial sequential monitoring boundaries for harm, benefit, or futility were crossed by the cumulative Z value." data-id="CD003328-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Trial Sequential Analysis of 15‐min infusion of acetylcysteine versus 60‐min infusion of acetylcysteine on any adverse event. The diversity‐adjusted required information size (DARIS) is 820 participants based on a proportion of 60% with the outcome in the control group (Pc); a risk reduction of 20%; an alpha (a) of 2.5%; a beta (b) of 20% (equivalent to a power of 80%); and an assumed diversity of 20%. As demonstrated the trial sequential monitoring boundaries for harm, benefit, or futility were crossed by the cumulative Z value. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methionine versus no intervention, Outcome 1 Mortality." data-id="CD003328-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Methionine versus no intervention, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methionine versus no intervention, Outcome 2 Hepatotoxicity (aspartate aminotransferase &gt; 1000 IU/L)." data-id="CD003328-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Methionine versus no intervention, Outcome 2 Hepatotoxicity (aspartate aminotransferase &gt; 1000 IU/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Cysteamine versus no intervention, Outcome 1 Mortality." data-id="CD003328-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Cysteamine versus no intervention, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Cysteamine versus no intervention, Outcome 2 Hepatotoxicity (aspartate aminotransferase &gt; 1000 IU/L)." data-id="CD003328-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Cysteamine versus no intervention, Outcome 2 Hepatotoxicity (aspartate aminotransferase &gt; 1000 IU/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Cysteamine versus methionine, Outcome 1 Mortality." data-id="CD003328-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Cysteamine versus methionine, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Cysteamine versus methionine, Outcome 2 Hepatotoxicity (aspartate aminotransferase &gt; 1000 IU/L)." data-id="CD003328-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Cysteamine versus methionine, Outcome 2 Hepatotoxicity (aspartate aminotransferase &gt; 1000 IU/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Cysteamine versus dimercaprol, Outcome 1 Mortality." data-id="CD003328-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Cysteamine versus dimercaprol, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Cysteamine versus dimercaprol, Outcome 2 Maximum alanine aminotransferase (IU/L)." data-id="CD003328-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Cysteamine versus dimercaprol, Outcome 2 Maximum alanine aminotransferase (IU/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Intravenous acetylcysteine versus 'placebo' in people with fulminant hepatic failure, Outcome 1 Mortality." data-id="CD003328-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Intravenous acetylcysteine versus 'placebo' in people with fulminant hepatic failure, Outcome 1 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Initial dose over 60 minutes versus 15 minutes of intravenous acetylcysteine, Outcome 1 Mortality." data-id="CD003328-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Initial dose over 60 minutes versus 15 minutes of intravenous acetylcysteine, Outcome 1 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Initial dose over 60 minutes versus 15 minutes of intravenous acetylcysteine, Outcome 2 Hepatotoxicity." data-id="CD003328-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Initial dose over 60 minutes versus 15 minutes of intravenous acetylcysteine, Outcome 2 Hepatotoxicity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Initial dose over 60 minutes versus 15 minutes of intravenous acetylcysteine, Outcome 3 Any adverse event." data-id="CD003328-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Initial dose over 60 minutes versus 15 minutes of intravenous acetylcysteine, Outcome 3 Any adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 12‐hour intravenous acetylcysteine regimen versus 20.5‐hour regimen, Outcome 1 Mortality." data-id="CD003328-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 12‐hour intravenous acetylcysteine regimen versus 20.5‐hour regimen, Outcome 1 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 12‐hour intravenous acetylcysteine regimen versus 20.5‐hour regimen, Outcome 2 Hepatotoxicity." data-id="CD003328-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 12‐hour intravenous acetylcysteine regimen versus 20.5‐hour regimen, Outcome 2 Hepatotoxicity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 12‐hour intravenous acetylcysteine regimen versus 20.5‐hour regimen, Outcome 3 Vomiting, retching, or antiemetics from 0 to 2 hour." data-id="CD003328-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 12‐hour intravenous acetylcysteine regimen versus 20.5‐hour regimen, Outcome 3 Vomiting, retching, or antiemetics from 0 to 2 hour. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 12‐hour intravenous acetylcysteine regimen versus 20.5‐hour regimen, Outcome 4 Vomiting, retching, or antiemetics 0 to 12 hour." data-id="CD003328-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 12‐hour intravenous acetylcysteine regimen versus 20.5‐hour regimen, Outcome 4 Vomiting, retching, or antiemetics 0 to 12 hour. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 12‐hour intravenous acetylcysteine regimen versus 20.5‐hour regimen, Outcome 5 Anaphylactoid symptoms (all)." data-id="CD003328-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 12‐hour intravenous acetylcysteine regimen versus 20.5‐hour regimen, Outcome 5 Anaphylactoid symptoms (all). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003328-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/urn:x-wiley:14651858:media:CD003328:CD003328-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_t/tCD003328-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Charcoal haemoperfusion versus no intervention, Outcome 1 Mortality." data-id="CD003328-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Charcoal haemoperfusion versus no intervention, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/media/CDSR/CD003328/image_n/nCD003328-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003328-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Methionine and supportive treatment compared with supportive treatment for paracetamol (acetaminophen) overdose</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Methionine and supportive treatment compared with supportive treatment (randomised trials) for paracetamol (acetaminophen) overdose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with paracetamol (acetaminophen) overdose<br/> <b>Settings:</b> UK<br/> <b>Intervention:</b> methionine and supportive treatment<br/> <b>Comparison:</b> supportive treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Supportive treatment </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Methionine and supportive treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 0.14</b><br/> (0.00 to 6.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>26<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The Trial Sequential Analysis‐adjusted CI could not be estimated due to the paucity of data. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/> (0 to 362) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hepatotoxicity</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.05</b><br/> (0.01 to 0.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>26<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>615 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000<br/> (16 to 459) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised clinical trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for risk of bias (concerns regarding randomisation sequence generation and allocation concealment probably compromised).<br/> <sup>2</sup>Downgraded two levels because of serious imprecision (due to small sample studied, low number of deaths, and wide confidence intervals).<br/> <sup>3</sup>Downgraded one level because of imprecision (due to small sample studied). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Methionine and supportive treatment compared with supportive treatment for paracetamol (acetaminophen) overdose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003328-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Cysteamine compared with no intervention for paracetamol (acetaminophen) overdose</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cysteamine compared with no intervention (randomised trials) for paracetamol (acetaminophen) overdose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with paracetamol (acetaminophen) overdose<br/> <b>Settings:</b> Royal Victoria Infirmary, Newcastle, UK<br/> <b>Intervention:</b> cysteamine<br/> <b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Cysteamine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 0.53</b><br/> (0.05 to 5.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>65<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000<br/> (3 to 252) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hepatotoxicity</b> (aspartate aminotransferase &gt; 1000 IU/L) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.09</b><br/> (0.02 to 0.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>65<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis‐adjusted CI ranged from 0.00 to 24.0.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>545 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 1000<br/> (23 to 290) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised clinical trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level because of risk of bias (method of randomisation had potential for bias and allocation concealment not specified).<br/> <sup>2</sup>Downgraded two levels because of serious imprecision (due to small sample studied, low number of deaths, and confidence intervals are wide).<br/> <sup>3</sup>Downgraded one level because of imprecision (due to small sample studied). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Cysteamine compared with no intervention for paracetamol (acetaminophen) overdose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003328-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Cysteamine compared with dimercaprol for paracetamol (acetaminophen) overdose</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cysteamine compared with dimercaprol (randomised trials) for paracetamol (acetaminophen) overdose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with paracetamol (acetaminophen) overdose<br/> <b>Settings:</b> UK<br/> <b>Intervention:</b> cysteamine<br/> <b>Comparison:</b> dimercaprol </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Dimercaprol </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Cysteamine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 0.14</b><br/> (0.00 to 6.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>52<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/> (0 to 214) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean maximum alanine aminotransferase</b> (IU/L) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean maximum alanine aminotransferase (IU/L) in the dimercaprol was 754</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean maximum alanine aminotransferase (IU/L) in the cysteamine group was 722 (IU/L)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Difference ‐32.00 (95% CI ‐512.9 to 448.9). The difference between the 2 groups was not significant. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised clinical trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels because of serious imprecision (due to small sample studied, low number of deaths, and confidence intervals wide).<br/> <sup>2</sup>Downgraded one level because of risk of bias (method of randomisation by envelopes and allocation not concealed).<br/> <sup>3</sup>Downgraded one level because of imprecision (due to small sample studied). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Cysteamine compared with dimercaprol for paracetamol (acetaminophen) overdose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003328-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Cysteamine compared with methionine (randomised trials) for paracetamol (acetaminophen) overdose</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cysteamine compared with methionine (randomised trials) for paracetamol (acetaminophen) overdose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with paracetamol (acetaminophen) overdose<br/> <b>Settings:</b> Newcastle (Royal Victoria Infirmary) and London (Guy's Hospital)<br/> <b>Intervention:</b> cysteamine<br/> <b>Comparison:</b> methionine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Methionine </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Cysteamine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hepatotoxicity</b> (aspartate aminotransferase &gt; 1000 U/L) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.92</b><br/> (0.05 to 16.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>71 per 1000<br/> (4 to 578) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised clinical trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level because of risk of bias (concerns regarding randomisation and allocation concealment not specified).<br/> <sup>2</sup>Downgraded two levels because of serious imprecision (due to small sample studied and low number of deaths).<br/> <sup>3</sup>Downgraded two levels because of serious imprecision (due to small sample studied and wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Cysteamine compared with methionine (randomised trials) for paracetamol (acetaminophen) overdose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003328-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Standard intravenous acetylcysteine regimen (20.5 hour) compared with shorter intravenous acetylcysteine regimen (12 hour) for paracetamol (acetaminophen) overdose</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Standard intravenous acetylcysteine regimen (20.5 hours) compared with shorter (12 hours) protocol for paracetamol (acetaminophen) overdose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with paracetamol (acetaminophen) overdose<br/> <b>Settings:</b> 3 acute clinical units in the UK<br/> <b>Intervention:</b> standard intravenous acetylcysteine regimen (20.25 hours)<br/> <b>Comparison:</b> shorter (12 hours) modified protocol </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Standard intravenous acetylcysteine regimen (20.25 hours)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Shorter (12‐hour protocol)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>222<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hepatotoxicity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.67</b> </p> <p>(0.11 to 4.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>202</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> <p>(3 to 111)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Vomiting, retching, or antiemetics</b> from 0‐2 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.30</b> </p> <p>(0.17 to 0.53)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>217<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>651 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>359 per 1000<br/> (241 to 498) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Vomiting, retching, or antiemetics</b> 0‐12 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.40</b> </p> <p>(0.22 to 0.75)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>203<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>784 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>593 per 1000<br/> (444 to 732) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Anaphylactoid symptoms</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.39</b> </p> <p>(0.21 to 0.70)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>208<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>750 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>539 per 1000<br/> (387 to 677) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised clinical trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level because of indirectness (a large number of prospective participants excluded prior to randomisation: 1539 judged suitable for treatment, only 222 randomised).<br/> <sup>2</sup>Downgraded two levels because of very serious imprecision (due to small sample studied and no deaths).<br/> <sup>3</sup>Downgraded two levels because of very serious imprecision (due to small sample studied, small numbers who developed hepatotoxicity, and wide confidence intervals).<br/> <sup>4</sup>Downgraded one level because of imprecision (due to small sample studied). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Standard intravenous acetylcysteine regimen (20.5 hour) compared with shorter intravenous acetylcysteine regimen (12 hour) for paracetamol (acetaminophen) overdose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003328-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Oral compared with intravenous acetylcysteine for paracetamol (acetaminophen) overdose</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral compared with intravenous acetylcysteine for paracetamol (acetaminophen) overdose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with paracetamol (acetaminophen) overdose<br/> <b>Settings:</b> Baharloo Hospital (Tehran)<br/> <b>Intervention:</b> oral acetylcysteine<br/> <b>Comparison:</b> intravenous acetylcysteine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Intravenous acetylcysteine </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Oral acetylcysteine </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>66<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hepatotoxicity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rates of hepatotoxicity not reported, only mean alanine aminotransferase between the 2 study groups. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nausea</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 2.71</b><br/> (1.00 to 7.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>66<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>333 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>575 per 1000<br/> (333 to 787) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Vomiting</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 2.10</b><br/> (0.62 to 7.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>66<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>152 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>273 per 1000<br/> (100 to 560) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised clinical trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level because of risk of bias (due to randomisation details or concealment allocation were not specified, participants were excluded from IV group if they developed an anaphylactoid reaction unresponsive to decreasing the administration rate. Unclear whether these participants were analysed and should have been included as intention‐to‐treat).<br/> <sup>2</sup>Downgraded one level because of risk of imprecision (due to small sample studied).<br/> <sup>3</sup>Downgraded one level because of indirectness (amount of paracetamol ingested mean dose of 160 mg/kg to 170 mg/kg is below the toxic dose that often requires treatment). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Oral compared with intravenous acetylcysteine for paracetamol (acetaminophen) overdose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003328-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Intravenous acetylcysteine compared with placebo in people with fulminant hepatic failure for paracetamol (acetaminophen) overdose</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous acetylcysteine compared with placebo in people with fulminant hepatic failure (randomised trials) for paracetamol (acetaminophen) overdose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with fulminant hepatic failure secondary to paracetamol (acetaminophen) overdose<br/> <b>Settings:</b> Liver Failure Unit, King's College Hospital <br/> <b>Intervention:</b> intravenous acetylcysteine<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Intravenous acetylcysteine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 0.29</b><br/> (0.09 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis‐adjusted CI ranged from 0.01 to 15.8.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>800 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>537 per 1000<br/> (265 to 790) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised clinical trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level because of risk of bias (randomisation and allocation concealment unclear).<br/> <sup>2</sup>Downgraded one level because of imprecision (small sample studied). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Intravenous acetylcysteine compared with placebo in people with fulminant hepatic failure for paracetamol (acetaminophen) overdose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003328-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Initial infusion rate of intravenous acetylcysteine over 15 minutes compared with 60 minutes for paracetamol (acetaminophen) overdose</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Initial infusion rate of intravenous acetylcysteine over 15 minutes compared with 60 minutes (randomised trials) for paracetamol (acetaminophen) overdose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with paracetamol (acetaminophen) overdose<br/> <b>Settings:</b> multicentre study conducted in tertiary referral hospitals in Australia<br/> <b>Intervention:</b> initial infusion of acetylcysteine over 15 minutes<br/> <b>Comparison:</b> initial infusion of acetylcysteine over 60 minutes </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Initial infusion over 15 minutes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Initial infusion over 60 minutes</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>180<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hepatotoxicity</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.34</b> </p> <p>(0.39 to 4.56)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000<br/> (23 to 213) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Any adverse event</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.51</b> </p> <p>(0.27 to 0.96)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>180<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis‐adjusted CI ranged from 0.36 to 11.0.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>752 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>608 per 1000<br/> (451 to 745) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised clinical trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level because of risk of bias (possible bias due to method of randomisation via "randomisation slips" in a "closed box," many participants lost to follow‐up, and uneven numbers between the 2 treatment groups with many more participants in the 15‐minute infusion group).<br/> <sup>2</sup>Downgraded two levels because of serious imprecision (due to small sample studied and no deaths).<br/> <sup>3</sup>Downgraded two levels because of serious imprecision (due to small sample studied, low rate of hepatotoxicity, and wide confidence intervals).<br/> <sup>4</sup>Downgraded one level because of imprecision (due to small sample). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Initial infusion rate of intravenous acetylcysteine over 15 minutes compared with 60 minutes for paracetamol (acetaminophen) overdose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003328-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Oral plus intravenous acetylcysteine compared with intravenous acetylcysteine for paracetamol (acetaminophen) overdose</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral and intravenous acetylcysteine compared with intravenous acetylcysteine for paracetamol (acetaminophen) overdose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with paracetamol (acetaminophen) overdose<br/> <b>Settings:</b> poisoning referral centre in Iran<br/> <b>Intervention:</b> oral and intravenous acetylcysteine<br/> <b>Comparison:</b> intravenous acetylcysteine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Intravenous acetylcysteine </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Oral and intravenous acetylcysteine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Primary outcome for this study was anaphylactoid reaction.</p> <p>Unable to analyse these results due to large number excluded from one arm.<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hepatotoxicity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised clinical trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels because of serious risk of bias (randomisation sequence generation and allocation concealment not recorded, and a large number of participants excluded (10 excluded from the 25 randomised)).<br/> <sup>2</sup>Downgraded two levels because of serious imprecision (due to small sample studied and no deaths). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Oral plus intravenous acetylcysteine compared with intravenous acetylcysteine for paracetamol (acetaminophen) overdose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003328-tbl-0010"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Charcoal haemoperfusion compared with no intervention for paracetamol (acetaminophen) overdose</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Charcoal haemoperfusion compared with no intervention (randomised trials) for paracetamol (acetaminophen) overdose</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with paracetamol (acetaminophen) overdose<br/> <b>Settings:</b> The Liver Unit, King's College Hospital, London UK<br/> <b>Intervention:</b> charcoal haemoperfusion<br/> <b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Charcoal haemoperfusion</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 7.39</b><br/> (0.15 to 372.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Note very small numbers in this trial; only 8 in each group.</p> <p>With only 1 death in the charcoal haemoperfusion arm.</p> <p>The Trial Sequential Analysis‐adjusted CI could not be calculated.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised clinical trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level because of risk of bias (randomisation sequence generation and allocation concealment not detailed).<br/> <sup>2</sup>Downgraded two levels because of serious imprecision (due to small sample studied and confidence intervals are very wide).<br/> <sup>3</sup>Downgraded one level because of risk of indirectness (imbalance between the two groups at baseline). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Charcoal haemoperfusion compared with no intervention for paracetamol (acetaminophen) overdose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/full#CD003328-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003328-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Methionine versus no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hepatotoxicity (aspartate aminotransferase &gt; 1000 IU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Methionine versus no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003328-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Cysteamine versus no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.05, 5.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hepatotoxicity (aspartate aminotransferase &gt; 1000 IU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.02, 0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Cysteamine versus no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003328-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Cysteamine versus methionine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hepatotoxicity (aspartate aminotransferase &gt; 1000 IU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.05, 16.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Cysteamine versus methionine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003328-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Cysteamine versus dimercaprol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Maximum alanine aminotransferase (IU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Cysteamine versus dimercaprol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003328-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Intravenous acetylcysteine versus 'placebo' in people with fulminant hepatic failure</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Intravenous acetylcysteine versus 'placebo' in people with fulminant hepatic failure</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003328-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Initial dose over 60 minutes versus 15 minutes of intravenous acetylcysteine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hepatotoxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Initial dose over 60 minutes versus 15 minutes of intravenous acetylcysteine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003328-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">12‐hour intravenous acetylcysteine regimen versus 20.5‐hour regimen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hepatotoxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Vomiting, retching, or antiemetics from 0 to 2 hour <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Vomiting, retching, or antiemetics 0 to 12 hour <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Anaphylactoid symptoms (all) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">12‐hour intravenous acetylcysteine regimen versus 20.5‐hour regimen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003328-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Charcoal haemoperfusion versus no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Charcoal haemoperfusion versus no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003328.pub3/references#CD003328-tbl-0018">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003328.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003328-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003328-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD003328-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD003328-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD003328-note-0002">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD003328-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD003328-note-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003328-note-0020">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003328\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003328\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003328\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003328\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003328\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003328\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003328\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003328\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003328\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003328\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003328\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003328\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003328\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003328\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003328\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003328\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003328\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003328\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003328.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003328.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003328.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003328.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003328.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729103864"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003328.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729103868"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003328.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed4bc5eb8f56f',t:'MTc0MDcyOTEwNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 